Page last updated: 2024-12-05

probucol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Probucol is a lipid-lowering agent that was initially developed as an antioxidant. It has a unique chemical structure, characterized by a diphenyl sulfide moiety, which contributes to its ability to lower cholesterol levels. Probucol acts by inhibiting the absorption of cholesterol from the gut and by increasing the excretion of cholesterol in the bile. It also possesses antioxidant properties, which may contribute to its cardioprotective effects. While probucol was once widely used, it has largely been replaced by newer lipid-lowering agents due to concerns about its potential side effects, including gastrointestinal disturbances, muscle aches, and drug interactions. However, research interest in probucol has resurfaced due to its potential in treating other conditions, such as neurodegenerative diseases, inflammatory disorders, and cancer. Current research is focusing on exploring the mechanisms underlying probucol's actions and its potential therapeutic applications beyond lipid lowering.'

Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4912
CHEMBL ID608
CHEBI ID8427
SCHEMBL ID4150
MeSH IDM0017604

Synonyms (184)

Synonym
probucolum [inn-latin]
brn 2026253
phenol, 4,4'-((1-methylethylidene)bis(thio))bis(2,6-bis(1,1-dimethylethyl))-
einecs 245-560-9
nsc 652160
nsc 86225
phenol, 4,4'-((1-methylethylidene)bis(thio))bis(2,6-bis(1,1-dimethylethyl)-
ccris 7510
acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
MLS000028492 ,
smr000058265
KBIO1_000599
DIVK1C_000599
sinlestal
lurselle
de-3872
nsc-652160
SPECTRUM_001296
SPECTRUM5_001343
PRESTWICK_408
NCGC00016777-01
cas-23288-49-5
PRESTWICK2_000384
CMAP_000039
lesterol
lorelco
lursell
2,6-ditert-butyl-4-[1-(3,5-ditert-butyl-4-hydroxy-phenyl)sulfanyl-1-methyl-ethyl]sulfanyl-phenol
dh 581
nsc652160
4,4'-(isopropylidenedithio)bis(2,6-di-tert-butylphenol)
bisphenabid
bisbid
panavir
dh-581
nsc86225
acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
acetone,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
nsc-86225
biphenabid
phenol,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-
BSPBIO_003176
BSPBIO_000567
IDI1_000599
PRESTWICK3_000384
AB00052202
23288-49-5
C07373
probucol
4,4'- (isopropylidenedithio)bis(2,6-di-tert-butylphenol)
DB01599
probucol (jp17/usp/inn)
D00476
lorelco (tn)
NCGC00094895-02
NCGC00094895-01
KBIO2_004344
KBIOGR_000708
KBIOGR_002394
KBIO2_002394
KBIO3_002396
KBIOSS_001776
KBIO2_004962
KBIO2_006912
KBIO3_002873
KBIOSS_002399
KBIO2_001776
KBIO2_007530
SPBIO_001420
NINDS_000599
SPECTRUM4_000414
SPECTRUM2_001400
SPBIO_002488
PRESTWICK1_000384
PRESTWICK0_000384
SPECTRUM3_001438
SPECTRUM1501109
BPBIO1_000625
NCGC00094895-03
NCGC00094895-04
superlipid
dh581
HMS2092D05
CHEMBL608 ,
chebi:8427 ,
HMS501N21
HMS1569M09
HMS1921D21
2,6-di-tert-butyl-4-[1-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-1-methyl-ethylsulfanyl]-phenol
2,6-di(tert-butyl)-4-{1-[3,5-di(tert-butyl)-4-hydroxyphenylsulfanyl]-1-methylethylsulfanyl}phenol
bdbm50007260
2,6-di-tert-butyl-4-(2-(3,5-di-tert-butyl-4-hydroxyphenylthio)propan-2-ylthio)phenol
2,6-di(tert-butyl)-4-{1-[3,5-di(tert-butyl)-4-hydroxyphenylsulfanyl]-1-methylethylsulfanyl}phenol(probucol)
2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol
AKOS001740866
4,4'-(propane-2,2-diyldisulfanediyl)bis(2,6-di-tert-butylphenol)
STK762566
HMS2096M09
2,6-bis(tert-butyl)-4-{1-[3,5-bis(tert-butyl)-4-hydroxyphenylthio]-isopropylth io}phenol
nsc-757837
pharmakon1600-01501109
nsc757837
tox21_110605
dtxsid2045440 ,
dtxcid0025440
P2002
HMS2233C08
BRD-K72029282-001-04-8
serterol
CCG-38986
NCGC00016777-02
NCGC00016777-05
NCGC00016777-03
NCGC00016777-04
p3cth044xj ,
probucolum
unii-p3cth044xj
probucol [usan:usp:inn:ban:jan]
acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
4,4'-(isopropylidenedithio)bis[2, 6-di-tert-butylphenol]
4,4'- (isopropylidenedithio)bis(2, 6-di-tert-butylphenol)
4,4'-(isopropylidenedithio)bis(2, 6-di-tert-butylphenol)
FT-0630498
NCGC00016777-07
S2119
gtpl7277
2,6-di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulfanyl]propan-2-yl}sulfanyl)phenol
probucol [usp-rs]
probucol [mi]
probucol [who-dd]
probucol [inn]
probucol [orange book]
probucol [usp impurity]
probucol [usan]
probucol [vandf]
probucol [mart.]
probucol [jan]
HY-B0388
SCHEMBL4150
NCGC00016777-08
tox21_110605_1
W-107409
4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)phenol]
phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-
acetone bis(3,5-di-t-butyl-4-hydroxyphenyl) mercaptole
2,6-ditert-butyl-4-((1-[(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl]-1-methylethyl)sulfanyl)phenol #
AC-31457
AB00052202_15
OPERA_ID_1820
AB00052202_14
mfcd00079281
SR-01000695447-3
sr-01000695447
SR-01000695447-2
4,4'-(propane-2,2-diylbis(sulfanediyl))bis(2,6-di-tert-butylphenol)
probucol, united states pharmacopeia (usp) reference standard
HMS3655P19
KS-1459
probucol, analytical standard
SBI-0051640.P002
HMS3713M09
SW196648-3
NCGC00016777-06
BCP06487
F20384
Z1544404498
probucol,(s)
Q10354103
BRD-K72029282-001-15-4
bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole acetone
EN300-122630
A918612
BP166196
HY-B0388R
CS-0694884
probucol (standard)
probucolo
c10ax02
4,4'-(propan-2,2-diylbis(sulfandiyl))bis(2,6-bis(1,1-dimethylethyl)phenol)
probucol (usp impurity)
probucol (usan:usp:inn:ban:jan)
probucol (usp-rs)
probucol (mart.)
probucolum (inn-latin)

Research Excerpts

Overview

Probucol (PBC) is a potent cholesterol-lowering drug. It has been studied extensively for its powerful antioxidative stress. Probucol is an antihyperlipidemic drug with potent antioxidant properties.

ExcerptReferenceRelevance
"Probucol (PBC) is a potent cholesterol-lowering drug and has been studied extensively for its powerful antioxidative stress. "( Probucol promotes osteoblasts differentiation and prevents osteoporosis development through reducing oxidative stress.
Li, TL; Tao, ZS; Wei, S, 2022
)
3.61
"Probucol is an antioxidant with a bis-phenol structure."( Research and Progress of Probucol in Nonalcoholic Fatty Liver Disease.
Chen, KQ; Cheng, L; Guan, MT; Ke, BY; Wang, SZ; Wang, ZB, 2023
)
1.93
"Probucol is a potent antioxidant and reduces tendon xanthomas in familial hypercholesterolemia patients despite reduction of high-density lipoprotein (HDL)-cholesterol (HDL-C)."( Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
Arai, H; Bujo, H; Doi, Y; Fukushima, M; Ishibashi, T; Kita, T; Masuda, D; Matsuzaki, M; Matsuzawa, Y; Nakagawa, S; Ohama, T; Saito, Y; Tanabe, K; Yamashiro, K; Yamashita, S; Yanagi, K, 2021
)
2.79
"Probucol (PB) is a drug that exhibits significant hydrophobicity and substantial intra and inter individual variability in oral absorption, with a miniature bioavailability and complex three compartmental pharmacokinetic modelling due to its high lipid affinity, low stability and high octanol to water partition coefficient. "( Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies.
Al-Salami, H; Gedawy, A; Golocorbin-Kon, S; Kovacevic, B; Mikov, M; Mooranian, A; Wagle, SR; Walker, D, 2020
)
2
"Probucol is an anti-hyperlipidemic agent and a potent antioxidant drug that can delay progression of diabetic nephropathy (DN) and reverses renal oxidative stress in diabetic animal models; however, the mechanisms underlying these effects remain unclear. "( Probucol ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc.
Chen, C; Han, Y; Hu, C; Kanwar, YS; Liu, F; Liu, Y; Sun, L; Xiao, L; Xiong, X; Yang, S; Zhan, M; Zhao, L; Zhou, Z; Zhu, X, 2017
)
3.34
"Probucol is an antihyperlipidemic drug with potent antioxidant properties. "( Probucol prevents the attenuation of β
Higashi, K; Ishii, K; Mori, A; Nakahara, T; Sakamoto, K; Wakao, S, 2017
)
3.34
"Probucol (PB) is an hypolipidaemic drug with potential antidiabetic effects. "( The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects.
Al-Salami, H; Al-Sallami, H; Mamo, J; Mooranian, A; Negrulj, R; Takechi, R, 2018
)
2.18
"Probucol (PB) is a lipophilic drug used for hypercholesterolemia and possesses desirable antidiabetic effects such as antioxidant and cell protective effects."( Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses.
Al-Salami, H; Arfuso, F; Goločorbin-Kon, S; Mikov, M; Mooranian, A; Stojanovic, G; Zamani, N, 2018
)
1.5
"Probucol is a cholesterol-lowering drug, while ursodeoxycholic acid is a hydrophilic bile acid."( Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes.
Al-Salami, H; Al-Sallami, H; Arfuso, F; Goločorbin-Kon, S; Kovacevic, B; Mikov, M; Mooranian, A; Takechi, R; Zamani, N, 2018
)
1.44
"Probucol (PB) is a highly lipophilic compound with very low and variable bioavailability."( Probucol Self-Emulsified Drug Delivery System: Stability Testing and Bioavailability Assessment in Human Volunteers.
Abd-Allah, F; Lila, A; Nada, A; Zaghloul, A, 2019
)
2.68
"Probucol is a controversial drug to inhibit ATP-binding cassette transporter A1 (ABCA1) and to exhibit some positive clinical effects such as regression of xanthomas. "( Selective Correction of Genotype Yield by Probucol in HDL-Deficient Mice Propagation.
Akita, N; Kobayashi, F; Tsujita, M; Yokota, T; Yokoyama, S, 2020
)
2.27
"Probucol is a lipid-lowering drug that is often prescribed for the treatment of familial hypercholesterolemia. "( Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits.
Bilal Waqar, A; Fan, J; Kang, D; Koike, T; Li, S; Liang, J; Niimi, M; Shiomi, M; Wang, Y, 2014
)
3.29
"Probucol is a lipid-lowering drug which has an anti-atherosclerosis effect."( Probucol via inhibition of NHE1 attenuates LPS-accelerated atherosclerosis and promotes plaque stability in vivo.
Chen, S; Feng, JD; Li, JF; Liu, XX; Zhang, MY, 2014
)
2.57
"Probucol (PB) is an antihyperlipidemic and antioxidant drug with the potential to show benefits in T2D."( Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol.
Al-Salami, H; Al-Sallami, HS; Arfuso, F; Chen-Tan, N; Fakhoury, M; Fang, Z; Golocorbin-Kon, S; Matthews, V; Mikov, M; Mooranian, A; Mukkur, TK; Negrulj, R; Watts, GF, 2014
)
1.35
"Probucol is a potent antioxidative drug that has been used for prevention and treatment of atherosclerotic cardiovascular diseases and xanthoma. "( Did we abandon probucol too soon?
Masuda, D; Matsuzawa, Y; Yamashita, S, 2015
)
2.21
"Probucol is a cholesterol-lowering drug that could reduce hERG current by decreasing plasma membrane hERG protein expression and eventually cause long QT syndrome."( Mechanisms underlying probucol-induced hERG-channel deficiency.
Geng, HZ; Li, BX; Liu, LR; Lv, L; Shi, YQ; Yan, CC; Yan, M; Zhang, X, 2015
)
1.45
"Probucol (PB) is a highly lipophilic, antihyperlipidemic drug with potential antidiabetic effects."( The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study.
Al-Salami, H; Arfuso, F; Mooranian, A; Negrulj, R, 2015
)
1.35
"Probucol (PB) is a lipophilic drug with potential applications in type 2 diabetes (T2D)."( Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line.
Al-Salami, H; Arfuso, F; Mooranian, A; Negrulj, R, 2016
)
1.44
"Probucol is a lipid-lowering agent with anti-oxidant effects. "( Effects of probucol on hepatic tumor necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 expression in diabetic rats.
Li, Z; Liu, D; Mei, Z; Shen, W; Xu, X; Zhang, X, 2009
)
2.19
"Probucol is a potent anti-oxidant drug that has been in clinical use during the past few decades for the treatment and prevention of cardiovascular diseases."( Where are we with probucol: a new life for an old drug?
Matsuzawa, Y; Yamashita, S, 2009
)
1.41
"Probucol is a cholesterol-lowering drug with an anti-proliferative effect. "( Janus kinase 2/signal transducers and activators of transcription signal inhibition regulates protective effects of probucol on mesangial cells treated with high glucose.
Du, J; Fan, Q; Feng, J; Liu, X; Luo, J; Ma, J; Wang, J; Wang, L; Yao, L; Zhou, H, 2010
)
2.01
"Probucol is a hypocholesterolemic agent that reduces amyloid burden in transgenic amyloid mice, but the mechanisms for this effect are presently unclear."( Probucol suppresses enterocytic accumulation of amyloid-β induced by saturated fat and cholesterol feeding.
Dhaliwal, S; Galloway, S; Mamo, JC; Pallebage-Gamarallage, MM; Takechi, R, 2012
)
2.54
"Probucol is a compound that reduces HDL-C levels but also reduces atherosclerosis in animal models and xanthomas in humans."( Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport.
Billheimer, JT; Komaru, Y; Li, X; Rader, DJ; Tanigawa, H; Yamamoto, S, 2011
)
1.09
"Probucol is a unique hypolipidemic agent that decreases high density lipoprotein cholesterol (HDL-C). "( Probucol alleviates atherosclerosis and improves high density lipoprotein function.
Guo, ZG; Lai, WY; Li, C; Tu, Y; Wang, ZK; Zhong, JK, 2011
)
3.25
"Probucol, which is a cholesterol-lowering drug and clinically reported to cause QT prolongation, potently inhibited the IKs in a concentration-dependent manner, with a half maximal inhibitory concentration of 149.1 nM."( Chronic probucol treatment decreases the slow component of the delayed-rectifier potassium current in CHO cells transfected with KCNQ1 and KCNE1: a novel mechanism of QT prolongation.
Arai, T; Miyamoto, N; Sawada, K; Taniguchi, T; Uesugi, M; Yoshinaga, T, 2012
)
1.53
"Probucol is a lipid-lowering agent with potent anti-oxidant properties once commonly used for the treatment of cardiovascular disease."( Probucol prevents blood-brain barrier dysfunction in wild-type mice induced by saturated fat or cholesterol feeding.
Dhaliwal, SS; Galloway, S; Lam, V; Mamo, JC; Pallebage-Gamarallage, MM; Takechi, R, 2013
)
2.55
"Probucol is a lipid-lowering phenolic compound with anti-inflammatory and antioxidant properties that has been recently reported as protective in neurotoxicity and neurodegeneration models."( Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease.
Colle, D; Dos Santos, AA; Farina, M; Figueiredo, CP; Moreira, EL; Peres, KC; Ribeiro, RP; Santos, DB, 2013
)
2.55
"Probucol is a lipid-lowering agent with an antioxidant effect; however, its influence on the liver remains unclear. "( Effects of probucol in hyperlipidemic rabbit liver: a preliminary ultrastructural study.
Aktuna Keskil, Z; Aşan, E; Korkusuz, P; Ugur, Y; Uluoglu, C, 2002
)
2.15
"Probucol is a lipid-lowering drug that has an antioxidant effect. "( Effect of antioxidant probucol for preventing stent restenosis.
Cha, KS; Han, JY; Kim, HJ; Kim, JS; Kim, MH, 2002
)
2.07
"Probucol is a lipid-lowering agent with strong antioxidant properties."( Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study.
Malekzadeh, R; Merat, S; Naserimoghadam, S; Rakhshani, N; Sohrabi, MR; Sohrabpour, AA; Sotoudeh, M, 2003
)
2.48
"Probucol is a lipid-lowering drug with strong antioxidant properties."( Effects of probucol on endothelial damage by 5-fluorouracil.
Albertsson, M; Cwikiel, M; Eskilsson, J; Kinhult, S, 2003
)
1.43
"Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation."( The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease.
Champagne, D; Dea, D; Pearson, D; Poirier, J; Rochford, J, 2003
)
1.33
"Probucol is known to be a potent hypolipidemic drug to regress xanthoma formation and carotid atherosclerosis in conjunction with a marked reduction in HDL-cholesterol levels."( Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism.
Hirano, K; Ikegami, C; Koseki, M; Maruyama, T; Masuda, D; Matsuura, F; Nakagawa-Toyama, Y; Shimomura, I; Tsujii, K; Ueda, Y; Yamashita, S; Zhang, Z, 2005
)
2.49
"Probucol is known to be a potent hypolipidemic drug to regress xanthoma formation and carotid atherosclerosis in conjunction with a marked reduction in HDL-cholesterol levels."( Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits.
Hong, SC; Wu, ZH; Zhao, SP, 2007
)
1.46
"Probucol is a hypolipidemic agent and has antioxidant activity, which may inhibit the oxidative modification of low-density lipoprotein cholesterol."( Pretreatment with probucol attenuates cardiomyocyte apoptosis in a rabbit model of ischemia/reperfusion.
Al-Ghazali, R; Jinzhen, W; Ruixing, Y; Wenwu, L, 2006
)
1.39
"Probucol is a clinically used cholesterol-lowering drug, with pronounced antioxidant properties. "( Probucol modulates iron nitrilotriacetate (Fe-NTA)-dependent renal carcinogenesis and hyperproliferative response: diminution of oxidative stress.
Iqbal, M; Okada, S; Okazaki, Y, 2007
)
3.23
"Probucol is a cholesterol-lowering agent that stimulates the uptake and retention of lipids carried by lipoproteins in peripheral tissues."( Probucol therapy overcomes the reproductive defect in CTP: phosphocholine cytidylyltransferase beta2 knockout mice.
Frank, M; Gunter, C; Jackowski, S; Murti, KG; Rehg, JE; Tian, Y, 2007
)
2.5
"Probucol is a unique hypolipidemic agent that increases cholesteryl ester transfer protein (CETP) activity. "( Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling.
Akamatsu, S; Hanyu, O; Hirayama, S; Ishikawa, Y; Miida, T; Miyazaki, O; Nakajima, K; Nakano, T; Okada, M; Okazaki, M; Saito, T; Seino, U, 2008
)
3.23
"Probucol is a diphenolic compound with anti-oxidant and anti-inflammatory properties that reduces atherosclerosis and restenosis. "( Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds.
Hime, N; Stocker, R; Tanous, D, 2008
)
2.04
"Probucol is a white, odourless crystalline powder, almost insoluble in water but soluble in most organic solvents."( [Probucol: chemical structure, physical properties and assay methods (author's transl)].
Pignard, P, 1980
)
1.89
"Probucol seems to be a non hepatotoxic drug and induces a decrease of lithogenic index of bile."( [Probucol: mechanism of action (author's transl)].
Infante, R, 1980
)
1.89
"probucol is a new hypolipaemic agent which differs from similar drugs in current use by its chemical structurae and, probably, by its mode of action. "( [The effects of probucol in man (author's transl)].
Leutenegger, M, 1980
)
2.05
"Probucol is a lipid-lowering agent which inhibits the oxidative modification of LDL."( Dipyridamole inhibits the oxidative modification of low density lipoprotein.
Ardlie, NG; Czeti, AL; McGuiness, JA; Selley, ML, 1994
)
1.01
"Probucol is a clinically important drug that decreases plasma cholesterol in humans and has a marked anti-atherogenic effect in hyperlipidaemic Watanabe rabbits. "( Effects of the synthetic anti-oxidant, probucol, on the U937 monoblastoid cell line.
Aruoma, OI; Brickell, PM; Davies, MJ; Faulkner, L; Halliwell, B; Katz, DR; Woolf, N, 1993
)
2
"Probucol is a potent inhibitor of atherosclerosis in animal models. "( Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis.
Fruebis, J; Gonzalez, V; Palinski, W; Silvestre, M, 1997
)
2.14
"Probucol is a powerful inhibitor of atherosclerosis in a number of animal models. "( Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice.
Bird, DA; Fruebis, J; Palinski, W; Steinberg, D; Tangirala, RK; Witztum, JL, 1998
)
2.15
"Probucol is an antihyperlipidemic agent with antioxidant effects and antiatherosclerotic properties in hypercholesterolemic conditions. "( Cardioprotective effect of probucol in the atherosclerosis-prone JCR:LA-cp rat.
Amy, RM; Dolphin, PJ; Graham, SE; Russell, JC, 1998
)
2.04
"Probucol (PBC) is an unique antiatherogenic drug producing its effect by antioxidant action rather than hypolipidaemic effect. "( Probucol inhibits oxidized-low density lipoprotein-induced adhesion of monocytes to endothelial cells by reducing P-selectin synthesis in vitro.
Chen, JX; Li, LX; Liao, DF; Yu, L, 1998
)
3.19
"Probucol is a cholesterol-lowering and antioxidant drug that has been shown to inhibit or delay the progression of atherosclerosis. "( The effect of probucol on oxidized cholesterol disposition in hyperlipidaemic patients.
Abo, K; Hashimoto, H; Inouye, M; Mio, T; Sumino, K; Tsuzuki, D,
)
1.93
"Probucol is a lipid-regulating drug that also has antioxidant properties. "( Radioprotection of the intestinal mucosa of rats by probucol.
Baptista, ML; Bonsack, ME; Delaney, JP; Felemovicius, I, 1999
)
2
"Probucol is a very strong synthetic antioxidant that was been safely used for the treatment of hyperlipidemia in Japan since 1985. "( An antioxidant, probucol, induces anti-angiogenesis and apoptosis in athymic nude mouse xenografted human head and neck squamous carcinoma cells.
Kawakami, K; Mizuno, H; Nishimura, G; Tsukuda, M; Yanoma, S, 1999
)
2.09
"Probucol is a potent inhibitor of atherosclerosis in animal models."( Selective inhibition by probucol of vascular cell adhesion molecule-1 (VCAM-1) expression in human vascular endothelial cells.
Ciechanowicz, A; Kaczmarczyk, M; Markiewski, M; Naruszewicz, M; Zapolska-Downar, D; Zapolski-Downar, A, 2001
)
1.34
"Probucol is a clinically used cholesterol-lowering drug, with pronounced antioxidant properties. "( Probucol and liver efficiency during chemically-induced hepatocarcinogenesis.
Al-Gharabli, N; el-Demerdash, E; el-Denshary, Eel-D; el-didi, M; Osman, AM,
)
3.02
"Probucol is a bisphenolic compound that lowers serum cholesterol and also has potent antioxidant properties. "( Effects of probucol in renal function and structure in rats with subtotal kidney ablation.
Klahr, S; Modi, KS; Purkerson, ML; Schreiner, GF, 1992
)
2.12
"Probucol is a lipid lowering agent with antioxidant properties which may protect the LDL from FR mediated damage."( Probucol, a superoxide free radical scavenger in vitro.
Belch, JJ; Bridges, AB; Scott, NA, 1991
)
2.45
"Probucol is a hypolipidemic agent that causes a marked decrease in high density lipoprotein (HDL) cholesterol. "( Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition.
Hogue, M; Marcel, YL; McPherson, R; Milne, RW; Tall, AR,
)
1.82
"Probucol is a drug that lowers plasma cholesterol in both humans and animals. "( Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol.
Chi, EM; Jackson, RL; Mao, SJ; Parker, RA; Yates, MT,
)
1.79
"Probucol is a lipid-lowering drug with a well-known antioxidant action."( Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia.
Bargalló, MT; Casals, I; LaVille, A; Masana, L; Plana, N; Solà, R, 1991
)
1.34
"Probucol is a widely prescribed lipid-lowering agent, the major effects of which are to lower cholesterol in both low- and high-density lipoproteins (LDL and HDL, respectively). "( Putative mechanisms of action of probucol on high-density lipoprotein apolipoprotein A-I and its isoproteins kinetics in rabbits.
Arakawa, K; Harada, R; Saito, Y; Saku, K; Sasaki, N; Takami, N; Ying, H, 1990
)
2
"Probucol is an orally active agent that can reduce total cholesterol and LDL-cholesterol."( Probucol: pharmacology and clinical application.
Eder, H; Frishman, W; Zimetbaum, P, 1990
)
2.44
"Probucol is a lipid-regulating agent structurally dissimilar to other known agents, with a unique pharmacodynamic and clinical profile. "( Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.
Brogden, RN; Buckley, MM; Goa, KL; Price, AH, 1989
)
3.16
"Probucol is a widely used serum-cholesterol lowering drug. "( Mode of hypocholesterolemic action of probucol in animals and man.
Beynen, AC, 1987
)
1.99
"Probucol is a drug that lowers both LDL and HDL cholesterol levels."( Lipoprotein fractions and receptors: a role for probucol?
Bilheimer, DW, 1986
)
1.25
"Probucol is a drug with hypolipidemic effect from the group of diphenols. "( [Clinical research on the hypolipidemic action of a probucol preparation].
Balabanski, L; Goranov, I; Kerekovska, M; Naumova, R, 1986
)
1.96
"Probucol is shown to be a better accelerator for lipid clearance in triton hyperlipidemia than clofibrate."( Effect of probucol on triton induced hyperlipidemias in CFY rats.
Krishnamurthy, A; Shridhar, DR; Thapar, GS, 1985
)
1.39

Effects

Probucol has a potent antioxidative effect, inhibits the oxidation of LDL, and reduces xanthomas. It can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia.

Probucol has been shown to inhibit the release of cellular lipid by helical apolipoprotein and thereby to reduce plasma high density lipoprotein. Probucol treatment has beneficial effects on serum parameters, hepatic steatosis, and lobular inflammation in high-fat diet-induced NASH.

ExcerptReferenceRelevance
"Probucol has a potent antioxidative effect, inhibits the oxidation of LDL, and reduces xanthomas."( Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.
Arai, H; Bujo, H; Fukushima, M; Kagimura, T; Kita, T; Masuda, D; Matsuzaki, M; Matsuzawa, Y; Ohama, T; Saito, Y; Yamashita, S, 2016
)
1.41
"Probucol has a long history of clinical application with established efficacy and safety profiles. "( Where are we with probucol: a new life for an old drug?
Matsuzawa, Y; Yamashita, S, 2009
)
2.13
"Probucol has a more pronounced health benefit than high-dose CoQ(10) supplementation and uniquely restores CoQ(9) content in mutant kidney."( Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice.
Chen, JY; Clarke, CF; Falk, MJ; Gasser, DL; Horyn, O; King, R; Maltzman, JS; Marbois, B; Nakamaru-Ogiso, E; Nissim, I; Okwuego, E; Ostrovsky, J; Peng, M; Polyak, E; Xie, LX; Zhang, Z, 2011
)
2.53
"Probucol has a major, and vitamin E a minor, effect on LDL resistance to oxidation but neither compound appears to alter forearm vascular responses in vivo."( The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans.
Brennan, GM; Bruce, I; Johnston, GD; McDowell, IF; McEneny, J; McVeigh, GE; Nicholls, DP; Trimble, ER; Young, IS, 1994
)
1.37
"Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia."( Medical management of hyperlipidemia and the role of probucol.
Davignon, J, 1986
)
1.24
"Probucol has been shown to inhibit the release of cellular lipid by helical apolipoprotein and thereby to reduce plasma high density lipoprotein. "( Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation.
Hayashi, M; Tsujita, M; Wu, CA; Yokoyama, S, 2004
)
3.21
"Probucol has been widely applied to treat hyperlipidaemia and atherosclerosis in clinic, but whether it can protect against AAA remains unknown."( Mechanisms underlying the inhibitory effects of probucol on elastase-induced abdominal aortic aneurysm in mice.
Anwaier, G; Cao, Y; Chen, C; Qi, R; Wang, Q; Wang, Y; Zhang, Q, 2020
)
1.54
"Probucol has antioxidant effects and inhibits inflammation. "( Probucol ameliorates hepatic stellate cell activation and autophagy is associated with farnesoid X receptor.
Hu, Z; Shen, X; Song, Z; Wei, Z; Wu, S; Yang, R; Zhang, P, 2019
)
3.4
"Probucol has significant add-on anti-atherosclerotic effects when combined with atorvastatin treatment; suggesting that this combination might be beneficial for treatment of atherosclerosis."( Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin.
Imaizumi, A; Itabe, H; Keyamura, Y; Kohashi, M; Koyama, T; Nagano, C; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T, 2014
)
2.18
"Probucol treatment has beneficial effects on serum parameters, hepatic steatosis, and lobular inflammation in high-fat diet-induced NASH possibly by up-regulating FXR expression."( [Effect of probucol in improving hepatic steatosis in rats with non-alcoholic steatohepatitis and the mechanism].
Gao, J; Liu, B; Wu, R; Wu, X; Xiao, X; Zhang, W; Zhang, X, 2014
)
2.23
"Probucol has been shown to prevent cerebral capillary disturbances characterized by blood-to-brain extravasation of plasma derived proteins and neurovascular inflammation in mice maintained on western-styled diets for 12 weeks. "( Long-term probucol therapy continues to suppress markers of neurovascular inflammation in a dietary induced model of cerebral capillary dysfunction.
Giles, C; Lam, V; Mamo, JC; Pallebage-Gamarallage, MM; Takechi, R, 2014
)
2.25
"Probucol has been used as a lipid-lowering drug for a long time especially in Japan, although Western countries quitted its use because of the reduction in serum HDL-cholesterol (HDL-C)."( Did we abandon probucol too soon?
Masuda, D; Matsuzawa, Y; Yamashita, S, 2015
)
1.49
"Probucol has pleiotropic and beneficial therapeutic effects on cardiovascular system. "( Did we abandon probucol too soon?
Masuda, D; Matsuzawa, Y; Yamashita, S, 2015
)
2.21
"Probucol has a potent antioxidative effect, inhibits the oxidation of LDL, and reduces xanthomas."( Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.
Arai, H; Bujo, H; Fukushima, M; Kagimura, T; Kita, T; Masuda, D; Matsuzaki, M; Matsuzawa, Y; Ohama, T; Saito, Y; Yamashita, S, 2016
)
1.41
"Probucol has a long history of clinical application with established efficacy and safety profiles. "( Where are we with probucol: a new life for an old drug?
Matsuzawa, Y; Yamashita, S, 2009
)
2.13
"Probucol has a more pronounced health benefit than high-dose CoQ(10) supplementation and uniquely restores CoQ(9) content in mutant kidney."( Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice.
Chen, JY; Clarke, CF; Falk, MJ; Gasser, DL; Horyn, O; King, R; Maltzman, JS; Marbois, B; Nakamaru-Ogiso, E; Nissim, I; Okwuego, E; Ostrovsky, J; Peng, M; Polyak, E; Xie, LX; Zhang, Z, 2011
)
2.53
"Probucol has anti-atherosclerotic properties and has been shown to reduce post-angioplasty coronary restenosis. "( Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis.
Amano, A; Daida, H; Kajimoto, K; Kasai, T; Kubota, N; Miyauchi, K, 2012
)
3.26
"Probucol has antioxidant as well as cholesterol-lowering effects. "( Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study.
Ban, N; Endo, K; Kawana, H; Miyashita, Y; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Oyama, T; Saiki, A; Sakuma, K; Sasaki, H; Shirai, K; Suzuki, Y; Tatsuno, I; Yamaguchi, T; Yamamura, S, 2013
)
3.28
"Probucol has also induced regression of carotid atherosclerosis in the Fukuoka Atherosclerosis Trial (FAST)."( Clinical results with AGI-1067: a novel antioxidant vascular protectant.
Tardif, JC, 2003
)
1.04
"Probucol has been reported to completely prevent DOX-induced cardiomyopathy."( New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
Ali, AA; El-Demerdash, E; Osman, AM; Sayed-Ahmed, MM, 2003
)
1.39
"Probucol has been recognized to have antioxidant properties as well as lipid-lowering effects, and may improve endothelial function."( Long-term treatment with probucol improves endothelial function in patients with coronary artery disease.
Kimura, Y; Ono, H; Suzuki, S; Tagawa, T; Takeda, K; Urabe, Y, 2004
)
1.35
"Probucol has reduced post-percutaneous coronary intervention (PCI) restenosis and progression of carotid atherosclerosis in clinical trials."( Antioxidants and atherosclerosis: emerging drug therapies.
Tardif, JC, 2005
)
1.05
"Probucol has antioxidant and cholesterol-lowering effects. "( Probucol delays progression of diabetic nephropathy.
Endo, K; Ito, Y; Koide, N; Miyashita, Y; Ohira, M; Otsuka, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006
)
3.22
"Probucol has reduced postpercutaneous coronary intervention (PCI)-restenosis and progression of carotid atherosclerosis in clinical trials."( Antioxidants: the good, the bad and the ugly.
Tardif, JC, 2006
)
1.06
"Probucol has anti-oxidant properties as well as cholesterol-lowering effects and may affect soluble thrombomodulin (sTM)."( Effect of the anti-oxidant probucol on soluble thrombomodulin (sTM) in hypercholesterolemic rabbits.
Hong, SC; Liu, Q; Wu, ZH; Zhao, SP, 2008
)
1.36
"Probucol has been reported to retard and even regress atherosclerosis in animal models and to diminish tendinous xanthomas in man."( [Probucol treatment of hyperlipidemia].
Koizumi, J, 1994
)
1.92
"Probucol has a major, and vitamin E a minor, effect on LDL resistance to oxidation but neither compound appears to alter forearm vascular responses in vivo."( The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans.
Brennan, GM; Bruce, I; Johnston, GD; McDowell, IF; McEneny, J; McVeigh, GE; Nicholls, DP; Trimble, ER; Young, IS, 1994
)
1.37
"Probucol has the drawback of decreasing high density lipoprotein concentration and is therefore unlikely to influence atheroma in people."( Antioxidants in the prevention of atherosclerosis.
Olsson, AG; Yuan, XM, 1996
)
1.02
"Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics. "( Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression.
Baldassarre, D; Brusoni, B; Franceschini, G; Peruzzotti, G; Sirtori, CR, 1997
)
2.05
"Probucol has been recognized to have antioxidant properties as well as lipid-lowering effects, and contribute to prevention of atherosclerosis. "( [Mechanisms of anti-atherogenic action of probucol].
Egusa, G; Ohya, T, 1999
)
2.01
"Probucol has been reported to completely prevent ADR cardiomyopathy without interfering with its antitumor effects."( Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats.
Belló-Klein, A; Danelisen, I; Li, T; Singal, PK, 2000
)
1.42
"Probucol has recently been shown to reduce the incidence of post-angioplasty restenosis in a number of small clinical trials, making it possible to reassess the validity of the rat balloon injury model."( Effects of probucol on rat carotid artery responses to balloon catheter injury.
Jackson, CL; Pettersson, KS, 2001
)
1.42
"Probucol has little effect on the solid to isotropic transition of cholesteryl oleate, but broadens and decreases the enthalpy of the liquid-crystalline transitions at concentrations as low as 1-2 mol %."( Modulation of the physical state of cellular cholesteryl esters by 4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol) (probucol).
Hagaman, KA; McLean, LR; Thomas, CE; Weintraub, B, 1992
)
1.21
"Probucol has been used as a lipid-lowering agent for over 10 years. "( Antiatherosclerotic effect of probucol in WHHL rabbits: are there plasma parameters to evaluate this effect?
Beisiegel, U; Finckh, B; Niendorf, A; Rath, M, 1991
)
2.01
"Probucol also has antioxidant activity, which may inhibit the oxidative modification of LDL that contributes to lipid deposition in blood vessel walls."( Probucol: pharmacology and clinical application.
Eder, H; Frishman, W; Zimetbaum, P, 1990
)
2.44
"Probucol has been investigated extensively in vivo and ex vivo. "( Probucol enhances cholesterol transport in cultured rat hepatocytes.
Barnhart, JW; Cheng, WD; Li, DL, 1988
)
3.16
"Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia."( Medical management of hyperlipidemia and the role of probucol.
Davignon, J, 1986
)
1.24
"Probucol has been shown to be an effective and well-tolerated cholesterol-lowering drug. "( Apolipoprotein E polymorphism and plasma cholesterol response to probucol.
Bouthillier, D; Davignon, J; Nestruck, AC; Sing, CF, 1987
)
1.95

Actions

Probu can suppress cell proliferation, down-regulate mRNA and protein levels of TGF-beta1 and CTGF in HMCs treated with high glucose. Probucol may cause degenerative changes on the liver parenchyme at the subcellular level.

ExcerptReferenceRelevance
"The probucol group had lower Cys-C and higher Ccr at 48 and 72 h after PCI compared with the control group."( The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018
)
1.31
"Probucol could inhibit intracellular ROS generation, promote proliferation, and decrease apoptosis of human retinal Müller cells cultured in high glucose. "( Probucol promotes high glucose-induced proliferation and inhibits apoptosis by reducing reactive oxygen species generation in Müller cells.
Ai, S; Chen, Z; Li, C; Zhou, X, 2019
)
3.4
"Probucol did not inhibit cholesterol synthesis and had no effect on I KCNQ1, while I(Ks) decreased after 24-h treatment."( Probucol and the cholesterol synthesis inhibitors simvastatin and triparanol regulate I ks channel function differently.
Hihara, T; Miyamoto, N; Sawada, K; Taniguchi, T; Ueda, M; Yoshinaga, T, 2013
)
2.55
"Probucol decreased the increase of CRP concentration and attenuated atrial oxidative stress caused by atrial tachypacing."( Probucol attenuates atrial autonomic remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing.
Dong, DL; Gong, YT; Li, BX; Li, WM; Li, Y; Liu, W; Shan, HB; Sheng, L; Xue, HJ; Yang, BF; Yang, N; Yang, SS, 2009
)
2.52
"Probucol can suppress cell proliferation, down-regulate mRNA and protein levels of TGF-beta1 and CTGF in HMCs treated with high glucose."( Janus kinase 2/signal transducers and activators of transcription signal inhibition regulates protective effects of probucol on mesangial cells treated with high glucose.
Du, J; Fan, Q; Feng, J; Liu, X; Luo, J; Ma, J; Wang, J; Wang, L; Yao, L; Zhou, H, 2010
)
1.29
"Probucol may cause degenerative changes on the liver parenchyme at the subcellular level."( Effects of probucol in hyperlipidemic rabbit liver: a preliminary ultrastructural study.
Aktuna Keskil, Z; Aşan, E; Korkusuz, P; Ugur, Y; Uluoglu, C, 2002
)
1.43
"This probucol-induced increase in HO-1 mRNA and inhibition of RASMC proliferation was prevented by the HO inhibitor Sn(IV) protoporphyrin or transfection with small interference RNA (siRNA) to knockdown HO-1, but not by inactive Cu(II) protoporphyrin or scrambled siRNA."( Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1.
Deng, YM; Stocker, R; Witting, PK; Wu, BJ, 2004
)
2.22
"Probucol did not increase human SR-BI protein in the liver of transgenic mice carrying the entire human SR-BI genome."( Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism.
Hirano, K; Ikegami, C; Koseki, M; Maruyama, T; Masuda, D; Matsuura, F; Nakagawa-Toyama, Y; Shimomura, I; Tsujii, K; Ueda, Y; Yamashita, S; Zhang, Z, 2005
)
2.49
"Probucol did not cause significant alterations in VLDL apo B turnover in 4 patients."( Effect of probucol on the composition of lipoproteins and on VLDL apoprotein B turnover.
Gonen, B; Kuisk, I; Lock, DR; Patsch, W; Schonfeld, G, 1983
)
1.39
"Probucol prevented the increase in lipid peroxides, but had no effect on plasma cholesterol."( Preservation of endothelium-dependent relaxation in atherosclerotic rabbit aorta by probucol.
Cohen, RA; Haudenschild, CC; Simon, BC, 1993
)
1.23
"Probucol is able to lower cholesterol levels in homozygous patients with familial hypercholesterolemia as well as in heterozygous patients."( [Probucol treatment of hyperlipidemia].
Koizumi, J, 1994
)
1.92
"Probucol may increase the QTc interval and may cause non-specific gastrointestinal complaints."( Currently available hypolipidaemic drugs and future therapeutic developments.
Farmer, JA; Gotto, AM, 1995
)
1.01
"Probucol was used because it is known to inhibit lipid peroxidation, but not protein modification."( Apolipoprotein B carbonyl formation is enhanced by lipid peroxidation during copper-mediated oxidation of human low-density lipoproteins.
Lodge, JK; Packer, L; Traber, MG; Yan, LJ, 1997
)
1.02
"Probucol inhibited the increase in the number of cultured VSMCs and bromodeoxyuridine (BrdU) incorporation stimulated by 10% FBS in a dose-dependent manner."( Probucol inhibits neointimal formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells.
Hayashi, K; Kajiyama, G; Kuga, Y; Nomura, K; Shingu, T; Tanaka, K, 1998
)
2.46

Treatment

Probucol did not significantly affect plasma concentrations of total cholesterol, unesterified cholesterol, triglycerides or phospholipids. Probucol treatment (0.5% in diet) resulted in reducing HDL cholesterol and serum apo A-I levels significantly.

ExcerptReferenceRelevance
"Probucol treatment prevented diabetes-induced lesions."( Probucol Prevents Diabetes-Induced Retinal Neuronal Degeneration through Upregulating Nrf2.
Chen, ZP; Liu, HW; Luo, Y; Zhou, YF, 2020
)
2.72
"Probucol treatment significantly decreased both the number of inflammatory cells in the bronchoalveolar lavage fluid and the degree of lung injury in hyperoxia-exposed mice."( Probucol attenuates hyperoxia-induced lung injury in mice.
Hamada, N; Harada-Ikeda, C; Kawaguchi, T; Kuwano, K; Maeyama, T; Nakanishi, Y; Suetsugu-Ogata, S; Suzuki, K; Yanagihara, T; Yokoyama, T, 2017
)
2.62
"The probucol-treated group showed significant decreases in E-selectin protein expression, myeloperoxidase activity, and malondialdehyde level and significant increase in testicular spermatogenesis in the ipsilateral testes, compared with the ischemia-reperfusion group."( Probucol Reduces Testicular Torsion/Detorsion-Induced Ischemia/Reperfusion Injury in Rats.
Huang, YM; Wei, SM; Zhou, J, 2017
)
2.38
"Probucol treatment significantly increased the ROSC rate and survival time of CA-induced rats. "( Probucol Protects Rats from Cardiac Dysfunction Induced by Oxidative Stress following Cardiopulmonary Resuscitation.
Che, B; Ho, D; Hou, H; Lin, V; Lu, Z; May, A; Shaw, PX; Tran, K; Xiao, X; Zhang, J, 2017
)
3.34
"Probucol co-treatment was associated with a 3.2-fold lower (p < 0.05) plasma HDL-cholesterol level and a more pro-inflammatory (CCR2+) monocyte phenotype."( HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution.
Hoekstra, M; Lendvai, Z; van der Sluis, RJ; Van Eck, M; Verwilligen, RAF; Wever, R, 2018
)
1.2
"Probucol treatment was initiated immediately after the induction of hyperglycemia was confirmed."( Probucol Slows the Progression of Cataracts in Streptozotocin-Induced Hyperglycemic Rats.
Higashi, K; Ishii, K; Mori, A; Nakahara, T; Sakamoto, K, 2019
)
2.68
"Probucol treatment attenuated bleomycin-induced TGF-β1 production, EMT and pulmonary fibrosis, meanwhile it suppressed bleomycin-induced oxidative stress."( Probucol ameliorates EMT and lung fibrosis through restoration of SIRT3 expression.
Li, HP; Li, YN; Liu, YJ; Wang, XL; Yang, T; Ye, CL; Zhang, HX; Zhu, XY, 2019
)
2.68
"Probucol treatment has beneficial effects on serum parameters, hepatic steatosis, and lobular inflammation in high-fat diet-induced NASH possibly by up-regulating FXR expression."( [Effect of probucol in improving hepatic steatosis in rats with non-alcoholic steatohepatitis and the mechanism].
Gao, J; Liu, B; Wu, R; Wu, X; Xiao, X; Zhang, W; Zhang, X, 2014
)
2.23
"Probucol treatment significantly protected against the behavioral and hippocampal biochemical changes induced by STZ."( Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice.
Colle, D; de Bem, AF; de Oliveira, J; Dos Santos, AA; Farina, M; Hort, MA; Moreira, ELG; Peres, KC; Ribeiro, RP; Santos, DB, 2015
)
2.58
"Probucol pre-treatment for 2 weeks and treatment throughout the infection rescued from death of mice infected with Plasmodium yoelii XL-17 or P."( Probucol-Induced α-Tocopherol Deficiency Protects Mice against Malaria Infection.
Hagihara, Y; Herbas, MS; Ishida, N; Kume, A; Shichiri, M; Suzuki, H; Yoshida, Y, 2015
)
2.58
"Probucol treatment improves erectile function by restoring endothelial function and preventing cavernous fibrosis in streptozotocin-induced diabetic rats."( Probucol Improves Erectile Function by Restoring Endothelial Function and Preventing Cavernous Fibrosis in Streptozotocin-induced Diabetic Rats.
Chen, D; Fu, Q; Li, B; Sun, DQ; Zhang, H; Zhang, KQ, 2016
)
3.32
"Probucol treatment normalized CET in all subjects and significantly lowered plasma cholesterol (pre-Rx: 197±4.5 vs post-Rx: 162±27.1mg/dL; mean±S.D.; p<.025) and HDL-C (pre-Rx: 46.4±7.5 vs post-Rx: 39.1±4.0; p<.025) without changing glycemic control."( Probucol normalizes cholesteryl ester transfer in type 2 diabetes.
Bagdade, JD; Lane, JT; Subbaiah, PV, 2016
)
2.6
"Probucol treatment paradoxically reduced plasma cholesterol levels, increased plasma cytokine levels and atherogenesis in apo E-KO mice. "( Pro-atherogenic effects of probucol in apo E-KO mice may be mediated through alterations in immune system: Parallel alterations in gene expression in the aorta and liver.
Azordegan, N; Le, K; Moghadasian, MH; Othman, RA; Xu, Z; Zhao, Z, 2009
)
2.09
"Probucol-treated mice could induce only a relatively minor corticosterone response upon a LPS challenge compared with controls, which coincided with an approximately twofold increased hepatic expression level of interleukin-6 and tumor necrosis factor (TNF)α and an 89% higher TNFα response in plasma."( Plasma lipoproteins are required for both basal and stress-induced adrenal glucocorticoid synthesis and protection against endotoxemia in mice.
Hoekstra, M; Korporaal, SJ; Li, Z; Van Berkel, TJ; Van Eck, M; Zhao, Y, 2010
)
1.08
"Probucol pretreatment not only counteracted significantly the CP-induced increase in cardiac enzymes and apoptosis but also it induced a significant increase in mRNA expression of antioxidant enzymes and improved ATP, ATP/ADP, glutathione (GSH) in cardiac tissues."( Probucol attenuates cyclophosphamide-induced oxidative apoptosis, p53 and Bax signal expression in rat cardiac tissues.
Asiri, YA,
)
2.3
"Probucol treatment increased plasma SOD, decreased plasma MDA and improved hypoinsulinaemia in diabetic rats."( Possible role for the thioredoxin system in the protective effects of probucol in the pancreatic islets of diabetic rats.
Lin, HL; Liu, DF; Liu, JH; Mei, X; Wang, NN, 2011
)
1.32
"Probucol-treated FH patients (n=21) showed a 47% reduction of serum HDL-C levels compared to probucol-untreated FH patients (n=15). "( Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia.
Inagaki, M; Ishigami, M; Kawase, M; Kawase, R; Komuro, I; Masuda, D; Matsuyama, A; Nakagawa-Toyama, Y; Nakaoka, H; Nakatani, K; Nishida, M; Ohama, T; Tsubakio-Yamamoto, K; Yamashita, S, 2012
)
2.22
"Probucol treatment prevented increases in oxidative stress, inflammation, and matrix metalloproteinase activity and attenuated LV dysfunction and remodeling."( Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation.
Egashira, K; Hayashidani, S; Machida, Y; Nakamura, R; Takeshita, A; Takeya, M; Tsutsui, H; Utsumi, H, 2002
)
2.48
"2) Probucol treated group: group 1 + intraperitoneal probucol (10 mg/kg/day) administration for 15 days."( Effects of probucol in hyperlipidemic rabbit liver: a preliminary ultrastructural study.
Aktuna Keskil, Z; Aşan, E; Korkusuz, P; Ugur, Y; Uluoglu, C, 2002
)
1.22
"Probucol treatment in these patients was also associated with protection of lipoproteins against oxidative stress, suggesting a clinical benefit of this drug even in such a state."( Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency.
Hara, M; Hashimoto, Y; Iso-o, N; Kawamura, M; Kimura, S; Noto, H; Satoh, H; Togo, M; Tsukamoto, K, 2003
)
1.32
"Probucol pretreatment of ABCA1-expressing fibroblasts reduced efflux to serum by 26%."( Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages.
Collins, HL; Duong, M; Favari, E; Jin, W; Rothblat, GH; Zanotti, I, 2006
)
1.06
"Probucol pretreatment apparently caused a decrease in the apoptotic index ((21.64 +/- 3.08) %, p < 0.01 versus the sham or control group) and serum MDA concentration (1.95 +/- 0.51 micromol/L, p < 0.01 versus the sham or control group), and increased the levels of serum SOD (162.61 +/- 16.13 microU/L, p < 0.01 versus the sham group; p < 0.05 versus the control group)."( Pretreatment with probucol attenuates cardiomyocyte apoptosis in a rabbit model of ischemia/reperfusion.
Al-Ghazali, R; Jinzhen, W; Ruixing, Y; Wenwu, L, 2006
)
1.39
"Probucol fed diet pretreatment also resulted a significant and dose dependent inhibition of Fe-NTA induced renal ornithine decarboxylase (ODC) activity."( Probucol modulates iron nitrilotriacetate (Fe-NTA)-dependent renal carcinogenesis and hyperproliferative response: diminution of oxidative stress.
Iqbal, M; Okada, S; Okazaki, Y, 2007
)
2.5
"In probucol treated patients QT interval prolongation was directly related to increasing probucol plasma levels (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)"( Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug.
Browne, KF; Cerimele, BJ; Fineberg, N; Heger, JJ; Prystowsky, EN; Zipes, DP, 1984
)
1.04
"Probucol treatment resulted in a decrease in plasma cholesterol and cholesterol 7 alpha-hydroxylase activity."( Effect of probucol on cholesterol metabolism in the rat.
Holets, RJ; Kottke, BA; Li, JR, 1980
)
1.38
"The probucol-treated M phi induced less marked increase of H2O2 in islet cells in comparison with control M phi."( Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice.
Fukuda, M; Ikegami, H; Kawaguchi, Y; Ogihara, T; Sano, T, 1995
)
1.14
"Probucol treatment was associated a threefold increase in LDL resistance to copper-induced oxidative modification (P < 0.05) and a reduction in tissue lipid peroxidation (as assessed by thiobarbituric acid-reactive substances; P < 0.05) compared to animals fed cholesterol alone."( Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation.
Cunningham, D; Frei, B; Jackson, T; Keaney, JF; Vita, JA; Xu, A, 1995
)
1.45
"(2) Probucol treatment in vitro had no effect on the basal or LPS-stimulated mRNA levels of IL-1 alpha, IL-1 beta, PDGF-A and PDGF-B despite its reported activity in vivo."( The effects of LPS and probucol on interleukin 1 (IL-1) and platelet-derived growth factor (PDGF) gene expression in the human monocytic cell line U-937.
Anggård, E; Ferns, G; Forster, L; Li, SR, 1994
)
1.08
"Probucol treatment led to a small increase in the surface expression of CD16 (Fc gamma RIII) in TNF-alpha treated cells and to a small decrease in the expression of CD14 (a monocyte marker) in PMA-treated cells."( Effects of the synthetic anti-oxidant, probucol, on the U937 monoblastoid cell line.
Aruoma, OI; Brickell, PM; Davies, MJ; Faulkner, L; Halliwell, B; Katz, DR; Woolf, N, 1993
)
1.28
"Probucol treatment results in a significant reduction of plasma high-density lipoprotein (HDL) levels. "( Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities.
Cassinotti, M; Chiesa, G; Franceschini, G; Gianfranceschi, G; Michelagnoli, S; Pazzucconi, F; Sirtori, CR; Werba, JP, 1993
)
1.98
"Probucol treatment results in an increase in plasma concentrations of cholesteryl ester transfer protein (CETP) which may account, in part, for the effects of this agent on plasma concentrations of HDL cholesterol. "( Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence.
Huerta, P; Marcel, YL; McPherson, R; Nancoo, D; Quinet, EM; Tall, AR, 1993
)
1.96
"3. Probucol treatment for 4 weeks lessened tobacco smoke-induced suppression of lung tissue glutathione, attenuated tobacco smoke-induced increases in lung tissue lipid peroxide and did not alter lung tissue tocopherol compared with control (lungs)."( Effect of probucol, an oral hypocholesterolaemic agent, on acute tobacco smoke inhalation in rats.
Ameshima, S; Ishizaki, T; Kishi, Y; Miyabo, S; Nakai, T; Sasaki, F, 1996
)
1.21
"In probucol-treated diabetic animals, LVSP was not different from controls."( Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy.
Hill, M; Kaul, N; Khaper, N; Singal, PK; Siveski-Iliskovic, N; Thomas, TP,
)
2.09
"Probucol treatment failed to induce any significant clastogenic, cytotoxic and biochemical changes."( Effect of probucol on the cytological and biochemical changes induced by adriamycin in Swiss albino mice.
al-Gharably, NM, 1996
)
1.42
"Probucol treatment also accelerated lesion development in apoE+/- mice fed an atherogenic diet, indicating that the adverse effect is not dependent on the complete absence of apoE."( Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.
Avdievich, E; Jones, RG; Maeda, N; Quarfordt, SH; Reddick, RL; Reynolds, JB; Surles, LK; Zhang, SH, 1997
)
1.28
"Probucol treatment completely prevented lesion formation in all animals up to 18 weeks of age."( Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis.
Fruebis, J; Gonzalez, V; Palinski, W; Silvestre, M, 1997
)
1.42
"Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics. "( Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression.
Baldassarre, D; Brusoni, B; Franceschini, G; Peruzzotti, G; Sirtori, CR, 1997
)
2.05
"Probucol treatment of corpulent male rats did not reduce plasma lipid concentrations or hyperinsulinemia."( Cardioprotective effect of probucol in the atherosclerosis-prone JCR:LA-cp rat.
Amy, RM; Dolphin, PJ; Graham, SE; Russell, JC, 1998
)
1.32
"Probucol treatment resulted in high plasma probucol concentrations, which correlated (r=0.69) with the lesion area."( Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action.
Frohlich, JJ; Godin, DV; McManus, BM; Moghadasian, MH; Rodrigues, B, 1999
)
1.28
"Probucol treatment modulated adriamycin-induced cardiomyopathic changes and increased glutathione peroxidase and superoxide dismutase activities."( Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy.
Danelisen, I; Hasinoff, BB; Iliskovic, N; Li, T; Malisza, KL; Singal, PK, 1999
)
1.3
"Probucol treatment prevented the formation of LPO products."( Puromycin-induced lipid peroxidation in the cochlea of ApoE knockout mice.
Aalto-Setälä, K; Aarnisalo, AA; Holthöfer, H; Ylikoski, J, 2000
)
1.03
"In probucol-treated patients, the cross-sectional area (CSA) narrowing of 67.6% or less was the best IVUS predictor for the absence of restenosis (P=0.03). "( Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial.
Bilodeau , L; Côté , G; Couturier , A; de Guise , P; Doucet , S; Gallo , R; Gosselin , G; Grégoire , J; Harel , F; Joyal , M; Lespérance , J; Tardif , JC, 2001
)
1.16
"Probucol treatment also significantly reduced high-density lipoprotein (HDL) levels in apoE-deficient mice, but not in LDLR-deficient mice."( Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice.
Chen, Z; Ishibashi, S; Shimano, H; Yamada, N; Yoshikawa, T, 2001
)
1.42
"Probucol treatment had no effect on the cardiac performance of the nondiabetic control rats."( Effects of probucol on impaired cardiac performance and lipid metabolism in streptozotocin-induced diabetic rats.
Kutsumi, Y; Miyabo, S; Nakai, T; Oida, K; Shimada, Y; Tada, H, 1992
)
1.39
"Probucol pretreatment enhanced the macrophage chemotactic responses to zymosan-activated serum, acetylated low density lipoprotein (LDL), and native LDL."( Probucol pretreatment enhances the chemotaxis of mouse peritoneal macrophages.
Hara, S; Kita, T; Nagano, Y; Sasada, M, 1992
)
2.45
"Probucol treatment significantly reduced the lipid concentration in all major lipoproteins, significantly reduced proteinuria and increased plasma albumin concentration."( Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis.
Hirano, T; Morohoshi, T, 1992
)
1.29
"Probucol treatment resulted in a change not only in the size but also the composition of lesions."( Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques.
Cho, M; Kita, T; Matsuzawa, Y; Nagano, Y; Nakamura, T; Ueda, Y, 1992
)
2.45
"Probucol treatment of nephrotic rats significantly lowered plasma triglyceride (TG), cholesterol (Ch) phospholipid (PL) and apoprotein B associated with very-low-density and low-density lipoprotein and Ch and PL in high-density lipoprotein (HDL)."( The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991
)
1.31
"Probucol treatment of these animals resulted in HDL with particle diameters of 9.4 and 8.5 nm, apparently reducing the size of the larger particles."( Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice.
Azrolan, N; Breslow, JL; Chajek-Shaul, T; Hayek, T; Walsh, A,
)
2.3
"1. Probucol treatment of mice (0.6 g/kg) induced a decrease of cholesterol (CH) and total phospholipids (PLs) in blood plasma, erythrocyte ghosts, liver plasma and microsomal membranes. "( Effect of probucol on the lipid composition of blood plasma, erythrocyte ghosts and liver membranes in mice.
Infante, R; Koumanov, KS; Markovska, TT; Momchilova-Pankova, AB; Neicheva, TN, 1990
)
1.3
"Probucol treatment for this period caused significant reductions in the serum levels of total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol, and apoprotein AI, AII, B, and CIII in both groups."( Effects of long-term treatment with probucol on serum lipoproteins in cases of familial hypercholesterolemia in the elderly.
Ishikawa, Y; Kobayashi, J; Mori, S; Morisaki, N; Saito, Y; Shinomiya, M; Shirai, K; Yoshida, S, 1990
)
1.28
"Probucol treatment had no effect on LPS-induced membrane IL 1 expression; secretion of tumor necrosis factor (TNF); Con A-induced splenic interleukin 2 (IL 2) and interleukin 3 (IL 3) release; and prostaglandin- or zymosan-induced secretion of prostacyclin, leukotriene C4, acid phosphatase, or superoxide anion."( Ex vivo lipopolysaccharide-induced interleukin-1 secretion from murine peritoneal macrophages inhibited by probucol, a hypocholesterolemic agent with antioxidant properties.
Dinerstein, RJ; Doherty, NS; Jackson, RL; Ku, G; Schmidt, LF, 1990
)
1.21
"Probucol treatment in hypercholesterolemic patients promotes the transfer of cholesteryl esters from high-density-lipoproteins (HDL) to lower-density lipoproteins. "( In vitro activity of probucol on cholesteryl ester transport.
Chiesa, G; Franceschini, G; Sirtori, CR, 1990
)
2.04
"3. Probucol treatment did not significantly affect plasma concentrations of total cholesterol, unesterified cholesterol, triglycerides or phospholipids."( Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits.
Daugherty, A; Schonfeld, G; Zweifel, BS, 1989
)
2.23
"Probucol treatment (0.5% in diet) resulted in reducing HDL cholesterol and serum apo A-I levels significantly, while pantethine treatment (0.25%-0.75% in diet) tended to increase HDL cholesterol and serum apo A-I levels."( Effect of probucol, pantethine and their combinations on serum lipoprotein metabolism and on the incidence of atheromatous lesions in the rabbit.
Ishihara, M; Ogawa, H; Tawara, K; Tomikawa, M, 1986
)
1.39
"Probucol treatment effectively decreased plasma cholesterol levels in both homozygous and heterozygous familial hypercholesterolemic subjects; however, the data suggest that the drug may exert different effects on sterol synthesis in peripheral tissues depending upon the presence or absence of cellular receptors for low-density lipoproteins."( Sterol synthesis in vitro in freshly isolated blood mononuclear leukocytes from familial hypercholesterolemic patients treated with probucol.
Bloch, CA; Botha, A; McNamara, DJ; Mendelsohn, D, 1985
)
1.19
"Treatment with probucol reduces the incidence of CI-AKI in patients undergoing contrast exposure during CAG or PCI. "( Probucol for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary intervention: A meta-analysis of randomized controlled trials
.
Jia, S; Lin, Z; Xin, W; Zhang, T, 2019
)
2.31
"Post-treatment with probucol at 3 mg/kg inhibited CFA-induced hyperalgesia over the course of 7 days as well as paw edema."( Probucol Ameliorates Complete Freund's Adjuvant-Induced Hyperalgesia by Targeting Peripheral and Spinal Cord Inflammation.
Badaro-Garcia, S; Borghi, SM; Camilios-Neto, D; Casagrande, R; Dos Santos, TS; Fattori, V; Manchope, MF; Verri, WA; Zucoloto, AZ, 2019
)
2.27
"Mice treated with Probucol had the drug incorporated into the chow at 1% (w/w)."( Probucol suppresses enterocytic accumulation of amyloid-β induced by saturated fat and cholesterol feeding.
Dhaliwal, S; Galloway, S; Mamo, JC; Pallebage-Gamarallage, MM; Takechi, R, 2012
)
2.15
"Treatment with probucol (30 µM) and lovastatin (1 µM and 3 µM), in addition to lecithinized-SOD, significantly inhibited the TGFβ1-induced formation of ROS and αSMA."( Inhibitory effects of clinical reagents having anti-oxidative activity on transforming growth factor-β1-induced expression of α-smooth muscle actin in human fetal lung fibroblasts.
Fujino, H; Kawashima, T; Makiyama, T; Matsuzawa, Y; Murayama, T; Yamaura, E; Yamazaki, R, 2011
)
0.71
"The treatment with probucol can improve oxidative stress in hypertension patients, resulting in reduced serum MDA levels and improved SOD activity, thus contributing agreater antihypertensive effect."( [Effect of probucol on serum malondialdehyde and superoxide dismutase in patients with primary hypertension].
Rong, H; Tan, M, 2012
)
1.1
"Treatment with probucol in vitro and inhibition of PON1 activity demonstrated that probucol in HDL particles and increase of PON1 activity might largely contribute to the increase of HDL anti-oxidative activity."( Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia.
Inagaki, M; Ishigami, M; Kawase, M; Kawase, R; Komuro, I; Masuda, D; Matsuyama, A; Nakagawa-Toyama, Y; Nakaoka, H; Nakatani, K; Nishida, M; Ohama, T; Tsubakio-Yamamoto, K; Yamashita, S, 2012
)
1.12
"Treatment with probucol (500 mg/day) resulted in the decrease in the levels of HDL-C and apolipoprotein (apo) A-I up to 22%."( Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency.
Hara, M; Hashimoto, Y; Iso-o, N; Kawamura, M; Kimura, S; Noto, H; Satoh, H; Togo, M; Tsukamoto, K, 2003
)
0.94
"Pretreatment with probucol (50 microM) inhibited (P < 0.001) both the apical-to-basal (-73.1%) and basal-to-apical (-77.8%) fluxes of [3H]-CsA."( Effect of probucol on the oral bioavailability of cyclosporine A.
Fujimura, A; Maezono, S; Sudoh, T; Sugimoto, K; Tsuruoka, S; Watanabe, Y; Yamamoto, Y, 2004
)
1.05
"Treatment with probucol (50 micromol/l) for 4 h prior to exposure to oxLDL significantly inhibited Daxx expression and THP-1 macrophage apoptosis by 61.3%."( Anti-apoptotic effects of probucol are associated with downregulation of Daxx expression in THP-1 macrophage.
Lei, XY; Liao, DF; Su, B; Tuo, QH; Yang, YB; Yin, W; Zhu, BY, 2007
)
0.98
"Treatment with probucol resulted in the regression of cutaneous and tendon xanthomas."( Effects of probucol on homozygous cases of familial hypercholesterolemia.
Hayashi, R; Hirobe, K; Kikkawa, T; Kishino, B; Matsuzawa, Y; Yamamoto, A, 1983
)
1
"Treatment with probucol resulted in the improvement of both hyperlipoproteinemia and proteinuria with the disappearance of the lipoprotein thrombi in the glomerular capillary without any change in the mesangial IgA deposition."( A case of lipoprotein glomerulopathy successfully treated with probucol.
Amenomori, M; Haneda, M; Hidaka, H; Kikkawa, R; Maeda, S; Morikawa, J; Nishigaki, I; Shigeta, Y, 1994
)
0.87
"Treatment with probucol was also accompanied by an increase in myocardial GSHPx and superoxide dismutase activities, with a concomitant decrease in lipid peroxidation."( Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats.
Kaul, N; Singal, PK; Siveski-Iliskovic, N, 1994
)
2.07
"Treatment with probucol (500 mg/day) or pravastatin (10 mg/day) reduced mean plasma total cholesterol concentrations by 24% (p < 0.01) and 16% (p < 0.05), respectively."( Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia.
Ishikawa, T; Kagami, A; Manabe, M; Mochizuki, K; Moriguchi, EH; Nagano, M; Sakamoto, T; Tada, N, 1993
)
1.02
"Treatment with probucol (10 mg/kg i.p., on alternate days), a known lipid-lowering drug with strong antioxidant properties, was initiated 1 d after the induction of diabetes and was continued for 4 wk."( Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy.
Hill, M; Kaul, N; Khaper, N; Singal, PK; Siveski-Iliskovic, N; Thomas, TP,
)
1.91
"Treatment with probucol or vitamin E significantly reduced the number of glomerular macrophages in the rats with PA-HC."( Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis.
Chung, HK; Jeong, JY; Kim, BC; Kim, YS; Lee, HS; Zhang, YZ, 1997
)
0.64
"Treatment with probucol (300 mg/kg/day, i.o.) was initiated 10 weeks after the induction of diabetes and was continued for 2 or 3 weeks."( Acute probucol treatment partially restores vasomotor activity and abnormal lipid metabolism whereas morphological changes are not affected in aorta from long-term STZ-diabetic rats.
Karasu, C, 1998
)
1.12
"Pretreatment with probucol attenuates reperfusion-induced decreases in LVV in the heterotopic rat heart isograft model. "( Attenuation of reperfusion injury with probucol in the heterotopic rat cardiac isograft.
Jia, CX; Rabkin, DG; Spotnitz, HM, 1999
)
0.91
"Treatment with probucol alone increased GSHPx activity at 2 weeks, and in these hearts, lipid peroxidation was lower than the control value."( Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol.
Li, T; Singal, PK, 2000
)
0.87
"Pretreatment with probucol (500 mg/kg, p.o.) also protected the gastric mucosa from endothelin-1-induced mucosal injury by its antioxidant activity."( Oxygen radicals mediate the final exacerbation of endothelin-1-induced gastric ulcer in rat.
Goto, K; Irukayama-Tomobe, Y; Lazaratos, S; Miyauchi, T; Nakahara, A, 2001
)
0.63
"Pretreatment with probucol significantly improved endothelium-dependent relaxation, decreased concentrations of ADMA and MDA and increased nitrite/nitrate level in the rats treated with LDL."( Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level.
Deng, HW; Jiang, JL; Li Ns, NS; Li, YJ, 2002
)
2.08
"Treatment with probucol, a widely used lipid-lowering agent, is associated with a significant reduction of high density lipoprotein (HDL) cholesterol levels, but with an apparently improved removal of cholesteryl esters from tissues (e.g., from tendon xanthomas). "( Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer.
Chiesa, G; Franceschini, G; Gianfranceschi, G; Rezzonico, L; Sirtori, CR; Sirtori, M; Vaccarino, V,
)
0.76

Toxicity

The oral LD50 of probucol in rats and mice was found to be higher than 5 000 mg/kg. The present study was designed to explore the toxic effect of MG on renal proximal tubular cells.

ExcerptReferenceRelevance
" Adverse side effects ranging from mere annoyances to uncommon serious consequences may be associated with dietary modification, recreational physical exercise, and drug intervention."( Adverse effects of the treatment for hyperlipidemia.
Malinow, MR, 1986
)
0.27
" d for more than 8 yr without adverse effect."( Eight-year toxicity study in monkeys and reproduction studies in rats and rabbits treated with probucol.
Barnard, SD; Gerbig, CG; LeBeau, JE; Molello, JA; Robinson, VB; Stephenson, MF; Thompson, DJ, 1980
)
0.48
"The oral LD50 of probucol in rats and mice was found to be higher than 5 000 mg/kg."( [Animal toxicity studies of probucol (author's transl)].
Lebeau, JE, 1980
)
0.89
"Oxidized low density lipoprotein (oxLDL) is known to be toxic to a variety of cell types, but relatively little is known about the toxic effects of oxLDL on vascular smooth muscle cells (SMC)."( Toxicity of oxidized low density lipoproteins for vascular smooth muscle cells and partial protection by antioxidants.
Guyton, JR; Hughes, H; Karsan, D; Lenz, ML; Mathews, B; Selinger, E; Smith, CV, 1995
)
0.29
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The present study was designed to explore the toxic effect of MG on renal proximal tubular cells as well as the protective effect of antioxidants PGE1 and probucol against MG-induced apoptosis in renal proximal tubular cells."( Methylguanidine cytotoxicity on HK-2 cells and protective effect of antioxidants against MG-induced apoptosis in renal proximal tubular cells in vitro.
Jiang, YS; Ling, GH; Wang, F; Yang, B; Yao, C, 2010
)
0.56
" Our data suggest that the two studied toxic models (QA and 3-NP) or the combined model (QA plus 3-NP) can generate complex patterns of damage, which involve metabolic compromise, ROS formation, and oxidative stress."( Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
Colle, D; Farina, M; Hartwig, JM; Soares, FA, 2012
)
1.82
"Polymer-free DESs are as safe and effective as durable polymer DES; however, there is no evidence of any additional benefits provided by this new technology."( Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients.
Angelini, P; Buffon, A; Cortese, B; de Boer, MJ; Dias, S; Kandzari, D; Kelm, M; Kowalewski, M; Kubica, J; Lansky, A; Navarese, EP; Suryapranata, H; Torguson, R; Waksman, R; Wojakowski, W, 2014
)
0.4

Pharmacokinetics

The purpose of this study was to clarify the mechanism of pharmacokinetic interaction between cyclosporin A and probucol in clinical cases.

ExcerptReferenceRelevance
"The bioavailability and pharmacokinetic behavior of 10 mg/kg of [14C]probucol in an oil-water emulsion was determined after oral and intravenous administration to rats."( Pharmacokinetics of probucol in male rats.
Heeg, JF; Hiser, MF; Rose, JQ; Satonin, DK, 1984
)
0.83
"The purpose of this study was to clarify the mechanism of pharmacokinetic interaction between cyclosporin A and probucol in clinical cases."( Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats.
Inui, K; Jiko, M; Saito, H; Wakasugi, H; Yano, I, 2002
)
0.76
" The pharmacokinetic parameters as well as relative bioavailability were analyzed."( [Pharmacokinetics and relative bioavailability of probucol inclusion complex capsule in healthy dogs].
Chen, BL; Fang, L; Fang, SQ; Gu, DL; Han, SJ; Huang, YL; Wang, K; Zhang, Z, 2002
)
0.57
" The Tmax values of formulation A and formulation B were (9."( [Pharmacokinetics and relative bioavailability of probucol inclusion complex capsule in healthy dogs].
Chen, BL; Fang, L; Fang, SQ; Gu, DL; Han, SJ; Huang, YL; Wang, K; Zhang, Z, 2002
)
0.57

Compound-Compound Interactions

Probucol combined with hydration more effectively decreased the incidence of CIN in patients with coronary heart disease undergoing PCI. Probucol and valsartan led to a more rapid decrease of 24-h urinary protein excretion.

ExcerptReferenceRelevance
" Fibrates also have the potential to cause rhabdomyolysis, although generally only in combination with HMG-CoA reductase inhibitors, and are subject to binding by concomitantly administered bile acid sequestrants."( Antihyperlipidaemic agents. Drug interactions of clinical significance.
Farmer, JA; Gotto, AM, 1994
)
0.29
" We therefore evaluated in 12 non-insulin-dependent diabetes mellitus subjects the effects of supplementation with alpha-tocopherol (1600 IU/d) and probucol (1 g/d) alone and in combination with an MUFA-enriched diet on LDL and LDL subfraction susceptibility to oxidation and monocyte release of superoxide anion."( Effect of antioxidants alone and in combination with monounsaturated fatty acid-enriched diets on lipoprotein oxidation.
Barnett, J; Grasse, B; Reaven, P, 1996
)
0.49
" For example, HMG-CoA reductase inhibitors may interact with macrolides, azalides, azole antifungals and cyclosporin."( Drug interactions of lipid-altering drugs.
Bays, HE; Dujovne, CA, 1998
)
0.3
" We investigated the efficacy and safety of probucol (an anti-oxidant) combined with valsartan (an ARB) on the progression of IgA nephropathy."( Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study.
Feng, Z; Hou, S; Hu, H; Liang, Y; Shi, W; Shi, X; Wang, L; Wang, W; Xia, Y; Xu, L; Yan, H; Ye, Z; Zhang, B; Zhang, L; Zhong, W, 2014
)
2.11
" Probucol combined with valsartan led to a more rapid decrease of 24-h urinary protein excretion than valsartan alone."( Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study.
Feng, Z; Hou, S; Hu, H; Liang, Y; Shi, W; Shi, X; Wang, L; Wang, W; Xia, Y; Xu, L; Yan, H; Ye, Z; Zhang, B; Zhang, L; Zhong, W, 2014
)
2.76
" The present randomized double-blind placebo-controlled multicenter clinical study evaluated the efficacy and safety of telmisartan combined with the antioxidant probucol in reducing urinary protein levels in patients with type 2 diabetes (T2D)."( Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study.
Cai, G; Chen, X; Guan, X; Li, J; Li, W; Liu, M; Liu, W; Liu, Y; Lun, L; Wang, Y; Wu, H; Yao, H; Yin, S; Zhang, J; Zheng, Y; Zhou, C; Zhu, H; Zhuang, X, 2016
)
0.93
"In patients with diabetic nephropathy, probucol combined with telmisartan more effectively reduces urinary protein levels than telmisartan alone."( Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study.
Cai, G; Chen, X; Guan, X; Li, J; Li, W; Liu, M; Liu, W; Liu, Y; Lun, L; Wang, Y; Wu, H; Yao, H; Yin, S; Zhang, J; Zheng, Y; Zhou, C; Zhu, H; Zhuang, X, 2016
)
1
"To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)."( The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018
)
1.09
"Probucol combined with hydration more effectively decreased the incidence of CIN in patients with coronary heart disease undergoing PCI compared with hydration alone."( The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018
)
2.27

Bioavailability

The bioavailability and pharmacokinetic behavior of 10 mg/kg of [14C]probucol in an oil-water emulsion was determined after oral and intravenous administration to rats. AGI-1067 is the metabolically stable monosuccinic acid ester of probucol, and a potent phenolic antioxidant.

ExcerptReferenceRelevance
"The bioavailability and pharmacokinetic behavior of 10 mg/kg of [14C]probucol in an oil-water emulsion was determined after oral and intravenous administration to rats."( Pharmacokinetics of probucol in male rats.
Heeg, JF; Hiser, MF; Rose, JQ; Satonin, DK, 1984
)
0.83
" Bile acid sequestrants are the most difficult of these agents to administer concomitantly, because their nonspecific binding results in decreased bioavailability of a number of other drugs, including thiazide diuretics, digitalis preparations, beta-blockers, coumarin anticoagulants, thyroid hormones, fibric acid derivatives and certain oral antihyperglycaemia agents."( Antihyperlipidaemic agents. Drug interactions of clinical significance.
Farmer, JA; Gotto, AM, 1994
)
0.29
" The results indicate that bioavailability of probucol is dependent on the lipid content of the diet."( Measurement of plasma probucol levels by high-performance liquid chromatography.
Anggård, EE; Ferns, GA; Forster, LA; Gopaul, NK; Nourooz-Zadeh, J, 1994
)
0.86
" Calculated bioavailability following oral administration of cyclosporin A decreased by 33% with the treatment of probucol."( Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats.
Fujimura, A; Sakamoto, K; Sugimoto, K, 1997
)
0.74
" Silybin was not so effective as silymarin suggesting that either other constituent(s) of silymarin may be responsible for its anticholesterolemic effect or the bioavailability of silybin alone might be lower than that of silybin as a compound of silymarin."( Silymarin inhibits the development of diet-induced hypercholesterolemia in rats.
Krecman, V; Simánek, V; Skottová, N; Ulrichová, J; Walterová, D, 1998
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"To study the pharmacokinetics and relative bioavailability of probucol inclusion complex capsule."( [Pharmacokinetics and relative bioavailability of probucol inclusion complex capsule in healthy dogs].
Chen, BL; Fang, L; Fang, SQ; Gu, DL; Han, SJ; Huang, YL; Wang, K; Zhang, Z, 2002
)
0.81
" The pharmacokinetic parameters as well as relative bioavailability were analyzed."( [Pharmacokinetics and relative bioavailability of probucol inclusion complex capsule in healthy dogs].
Chen, BL; Fang, L; Fang, SQ; Gu, DL; Han, SJ; Huang, YL; Wang, K; Zhang, Z, 2002
)
0.57
"The high bioavailability by the inclusion of formulation B is attributed to the improvement of its water-solubility by the inclusion process and this is supposed to be a key factor for improving drug bioavailability."( [Pharmacokinetics and relative bioavailability of probucol inclusion complex capsule in healthy dogs].
Chen, BL; Fang, L; Fang, SQ; Gu, DL; Han, SJ; Huang, YL; Wang, K; Zhang, Z, 2002
)
0.57
" Recently, a new microemulsion formulation of CyA(Neoral) has been developed and used preferably because of a more stable bioavailability than an oily formulation(Sandimmun)."( [Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)].
Inui, K; Muso, E; Ono, T; Wakasugi, H; Yoshimoto, M, 2002
)
0.7
"We have previously reported the reduction in oral bioavailability of cyclosporine A (CsA) by probucol, a lipid-lowering drug."( Effect of probucol on the oral bioavailability of cyclosporine A.
Fujimura, A; Maezono, S; Sudoh, T; Sugimoto, K; Tsuruoka, S; Watanabe, Y; Yamamoto, Y, 2004
)
0.95
" Dose-response curves of the probucol groups showed an improvement in endothelium-dependent relaxations, associated with increased nitric oxide bioavailability and decreased angiotensin II and hydroperoxide levels."( Role of probucol on endothelial dysfunction of epicardial coronary arteries associated with left ventricular hypertrophy.
Aubin, MC; Carrier, M; Perrault, LP; Shi, YF; Tardif, JC, 2006
)
1.06
" AGI-1067 is the metabolically stable monosuccinic acid ester of probucol, and a potent phenolic antioxidant representing a novel class of orally bioavailable compounds termed vascular protectants."( AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Eisert, C; Malinin, A; Ong, S; Serebruany, VL, 2007
)
0.58
" In conclusion, preparation of probucol nanoparticles by co-grinding with PVP K12 and SDS could be a promising method for bioavailability enhancement."( In vivo assessment of oral administration of probucol nanoparticles in rats.
Moribe, K; Pongpeerapat, A; Shudo, J; Wanawongthai, C; Yamamoto, K, 2008
)
0.89
" The formulations were evaluated in a bioavailability study in fasted and fed Göttingen minipigs using probucol as model drug."( Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state.
Müllertz, A; Nielsen, FS; Petersen, KB, 2008
)
0.89
" These release profiles compared with plasma profiles obtained in a previous bioavailability study conducted in mini-pigs at the same conditions."( In vitro-in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks.
Douroumis, D; Fatouros, DG; Hadjileontiadis, LJ; Mullertz, A; Nielsen, FS, 2008
)
0.35
" The prepared PBSEDDS may have the potential to enhance the therapeutic bioavailability of probucol."( Preparation, characterization and optimization of probucol self-emulsified drug delivery system to enhance solubility and dissolution.
Al-Saidan, S; Khattab, I; Nada, A; Zaghloul, A, 2008
)
0.82
" Therefore, it is essential to develop approaches to increase its solubility and bioavailability and to enhance the efficiency of the drug."( Nanoparticle processing in the solid state dramatically increases the cell membrane permeation of a cholesterol-lowering drug, probucol.
Fukami, T; Io, T; Ishii, T; Ramamoorthy, A; Suzuki, N; Suzuki, T; Tomono, K; Xu, J; Yamamoto, K,
)
0.34
" Previous results suggest that vascular dysfunction in OZR is associated with chronic reduction in vascular nitric-oxide (NO) bioavailability and chronic inflammation, both frequently associated with hypercholesterolemia."( Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA, 2009
)
0.35
"While the positive impact of chronic statin treatment on vascular outcomes in the metabolic syndrome are independent of changes to total cholesterol, and are more strongly associated with improvements to vascular NO bioavailability and attenuated inflammation, these results provide both a spatial and temporal framework for targeted investigation into mechanistic determinants of vasculopathy in the metabolic syndrome."( Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA, 2009
)
0.35
"The capability of transglycosylated materials, α-glycosyltransferase-treated stevia (Stevia-G) and α-glycosyl hesperidin (Hsp-G), to enhance the bioavailability of poorly water-soluble drugs was investigated."( Transglycosylated stevia and hesperidin as pharmaceutical excipients: dramatic improvement in drug dissolution and bioavailability.
Imono, M; Takeuchi, H; Tozuka, Y; Uchiyama, H, 2010
)
0.36
"Synthesis, detailed structural characterization (X-ray, NMR, MS, IR, elemental analysis), and studies of toxicity, antioxidant activity and bioavailability of unique potent anti-atherosclerotic succinobucol-steroid conjugates are reported."( Succinobucol's new coat--conjugation with steroids to alter its drug effect and bioavailability.
Buřičová, L; Drašar, P; Galandáková, A; Horníček, J; Ikonen, S; Jurček, O; Kolehmainen, ET; Ulrichová, J; Wimmer, Z; Wimmerová, M, 2011
)
0.37
"The objective of our investigation was to design a self-microemulsifying drug-delivery system (SMEDDS) to improve the bioavailability of probucol."( Self-microemulsifying drug-delivery system for improved oral bioavailability of probucol: preparation and evaluation.
Chen, Y; Fang, X; Sha, X; Wu, J, 2012
)
0.81
"The aim of this study was to enhance the dissolution rate and oral bioavailability of probucol."( Porous aerosil loading probucol using supercritical carbon dioxide: preparation, in vitro and in vivo characteristics.
Cai, C; Chu, C; Guan, J; Liu, M; Sun, Y; Wang, D; Zhang, T, 2014
)
0.94
"In order to investigate the influence of drug physicochemical properties on bioavailability of water insoluble drug nanosuspensions, five drug nanosuspensions were prepared using high pressure homogenization."( Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions.
Cheng, J; Cun, D; Fang, L; Li, W; Liu, J; Quan, P; Xiang, R; Zhang, Y, 2014
)
0.4
" Moreover, the oral bioavailability of probucol is significantly higher-13."( Nanoassembly of probucol enables novel therapeutic efficacy in the suppression of lung metastasis of breast cancer.
Cao, H; He, X; Jiang, S; Li, Y; Liu, Z; Yu, H; Zhang, Z, 2014
)
1.02
"To enhance the aqueous solubility and thus oral bioavailability of a poorly water-soluble drug, probucol (PB), probucol-phospholipid complex (PB-PC) was formulated by solvent-evaporation or co-grinding methods."( Application of phospholipid complex technique to improve the dissolution and pharmacokinetic of probucol by solvent-evaporation and co-grinding methods.
Guo, B; Li, Y; Liu, H; Wang, X; Yang, D; Zhang, T; Zhao, J, 2014
)
0.84
" Furthermore, the oral bioavailability of SCB was greatly improved about 13-fold by SN, and the biodistribution in major organs was evidently enhanced."( Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression.
Cao, H; Chen, L; Gu, W; He, X; Li, Y; Yin, Q; Yu, H; Zhang, Z; Zhao, S, 2015
)
0.42
" Lipid-based formulations have been proved to be an effective way to improve systemic bioavailability of highly lipophilic drugs by increasing intestinal lymphatic transport."( Lymphatic transport of orally administered probucol-loaded mPEG-DSPE micelles.
Han, L; Qing, J; Shen, T; Wang, J; Yang, Q, 2016
)
0.7
"This work aimed to improve the oral bioavailability and plasma lipid-lowering effect of probucol (PB) by constructing a combined drug delivery system (CDDS) composed of nanostructured lipid carrier (NLC) and PEGylated poly(amidoamine) dendrimer (PEG-PAMAM)."( G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
Banaszak Holl, MM; Cao, YN; Chen, C; He, B; Jie, X; Ke, X; Li, YZ; Liu, GQ; Qi, R; Shen, WW; van Dongen, MA; Wang, YN; Xu, L; Yu, MM; Zhang, Q, 2015
)
0.84
" PB has low bioavailability and high inter-individual variations in absorption, which limits its clinical applications."( The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study.
Al-Salami, H; Arfuso, F; Mooranian, A; Negrulj, R, 2015
)
0.62
" It is estimated that about 40% of drugs in the development pipeline and approximately 60% of the drugs coming directly from discovery suffer from poor aqueous solubility and slow dissolution, thereby reducing their bioavailability and efficacy and thus preventing their commercialization."( High-Throughput Raman Spectroscopy Screening of Excipients for the Stabilization of Amorphous Drugs.
Chen, X; Kalantar, TH; Kuo, TC; Ladika, M; Stoneburner, K, 2015
)
0.42
" The properties of the milled mixtures including morphology, crystal form, vitro drug dissolution and in vivo oral bioavailability in rats were evaluated."( Improved oral bioavailability of probucol by dry media-milling.
Li, J; Ma, J; Wang, S; Xu, H; Yang, Y; Zhao, M, 2017
)
0.74
" PB is highly hydrophobic and has poor bioavailability with significant inter- and intra-patient absorption, limiting its clinical applications in diabetes."( Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses.
Al-Salami, H; Arfuso, F; Goločorbin-Kon, S; Mikov, M; Mooranian, A; Stojanovic, G; Zamani, N, 2018
)
0.77
"To enhance the bioavailability and brain uptake of probucol and examine whether it attenuates neuroinflammation and neurodegeneration by utilizing a sodium alginate nanoencapsulation technique."( Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration.
Al-Salami, H; Brook, E; D'Alonzo, Z; Fimognari, N; Graneri, L; Lam, V; Mamo, JC; Mooranian, A; Nesbit, M; Stephenson, A; Takechi, R, 2018
)
0.98
"The objectives of this study were to examine the stability and conduct bioavailability of the prepared Probucol Self-Emulsified Drug Delivery System (PBSEDDS) in human volunteers."( Probucol Self-Emulsified Drug Delivery System: Stability Testing and Bioavailability Assessment in Human Volunteers.
Abd-Allah, F; Lila, A; Nada, A; Zaghloul, A, 2019
)
2.17
" The optimized formulations were evaluated for stability at different storage temperatures and human bioavailability compared with the drug dissolved in soybean oil (reference)."( Probucol Self-Emulsified Drug Delivery System: Stability Testing and Bioavailability Assessment in Human Volunteers.
Abd-Allah, F; Lila, A; Nada, A; Zaghloul, A, 2019
)
1.96
" The percentage relative bioavailability was in this order: F3> F4> F1> F2>."( Probucol Self-Emulsified Drug Delivery System: Stability Testing and Bioavailability Assessment in Human Volunteers.
Abd-Allah, F; Lila, A; Nada, A; Zaghloul, A, 2019
)
1.96
" All the formulations showed significant enhancement of bioavailability compared with the reference."( Probucol Self-Emulsified Drug Delivery System: Stability Testing and Bioavailability Assessment in Human Volunteers.
Abd-Allah, F; Lila, A; Nada, A; Zaghloul, A, 2019
)
1.96
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Probucol (PB) is a drug that exhibits significant hydrophobicity and substantial intra and inter individual variability in oral absorption, with a miniature bioavailability and complex three compartmental pharmacokinetic modelling due to its high lipid affinity, low stability and high octanol to water partition coefficient."( Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies.
Al-Salami, H; Gedawy, A; Golocorbin-Kon, S; Kovacevic, B; Mikov, M; Mooranian, A; Wagle, SR; Walker, D, 2020
)
2

Dosage Studied

Probucol, in a dosage of 500 mg twice daily, produced a 10% or greater reduction in serum cholesterol levels in all 11 patients. Probucol significantly suppressed the neuroinflammation and neurodegeneration.

ExcerptRelevanceReference
" Probucol, in a dosage of 500 mg twice daily, produced a 10% or greater reduction in serum cholesterol levels in all 11 patients."( Probucol: a new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia.
Mason, DT; Price, J; Salel, AF; Sodhi, HS; Zelis, R, 1976
)
2.61
" In 32 patients with Type II HL and 12 with Type IIB HL, statistically significant reduction in mean serum cholesterol levels occurred within two weeks and persisted throughout two years of therapy at constant dosage (500 mg."( Effect of probucol in hyperlipidemic patients during two years of administration.
Parsons, WB, 1978
)
0.66
"A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia."( A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV.
, 1990
)
0.75
" Probucol was administered in a dosage of 500 mg twice daily for 3 months."( Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with and without apolipoprotein E4.
Eto, M; Iwashima, Y; Makino, I; Sato, T; Watanabe, K, 1990
)
1.58
" Resident peritoneal macrophages from mice dosed with probucol secreted 40-80% less IL 1 than macrophages from control animals when stimulated in vitro with lipopolysaccharide (LPS)."( Ex vivo lipopolysaccharide-induced interleukin-1 secretion from murine peritoneal macrophages inhibited by probucol, a hypocholesterolemic agent with antioxidant properties.
Dinerstein, RJ; Doherty, NS; Jackson, RL; Ku, G; Schmidt, LF, 1990
)
0.74
"7%) on probucol reported mild to moderately severe side-effects, mainly gastro-intestinal, but in no case was treatment interrupted, although benzafibrate dosage was temporarily reduced."( Comparative study of bezafibrate and probucol in hyperlipidaemia.
González, G; Páez Moreno, JP, 1989
)
1.01
" These findings suggest that there is an optimum dosage of probucol to lower LDL + VLDL cholesterol and the atherogenic index, and that the actual optimum dosage for the beneficial effect depends on blood lipid levels or types of hyperlipidemia."( Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.
Abiko, Y; Nakayasu, T; Tawara, K; Tomikawa, M, 1981
)
0.91
" The daily dosage of probucol was 1 g divided into two 500 mg doses."( [A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)].
Cerimelle, BJ; Martz, BL; Taylor, HA; Tedeschi, RE, 1980
)
0.82
" One was designed to compared rat liver cell ultrastructure during and after 91 d of dosing with probucol, a hypocholesterolemic agent, and clofibrate, a hypolipidemic drug known to elicit marked alteration of rat hepatocellular morphology."( Comparative ultrastructural study of rat hepatocytes after treatment with the hypolipidemic agents probucol, clofibrate, and fenofibrate.
Barnard, SD; Caldwell, WJ; LeBeau, JE; Molello, JA, 1980
)
0.7
" Repeated administration of probucol to healthy volunteers showed good correlation between dosage and blood levels."( [Plasma levels of probucol in man after single and repeated oral doses (author's transl)].
Heeg, JF; Tachizawa, H, 1980
)
0.89
" However, during more prolonged administration (90 days) sudden death occurred in some animals, which was unrelated to dosage or to duration of treatment."( [Animal toxicity studies of probucol (author's transl)].
Lebeau, JE, 1980
)
0.56
"Native or irradiated crotoxin (iCTX) (50 microg/ml) dosed with 2 kGy 60Co gamma-rays (dose-rate 540 Gy/h) were offered to mouse peritoneal macrophages; their uptake was evaluated by immunohistochemistry and quantitative in situ ELISA."( Irradiation of Crotalus durissus terrificus crotoxin with 60Co gamma-rays induces its uptake by macrophages through scavenger receptors.
Andrade, HF; Cardi, BA; Nascimento, N, 1998
)
0.3
" In animals receiving pravastatin and the enriched diet (verum group; n = 6), mean total serum cholesterol levels were consistently lowered at a dosage of 5 mg/kg pravastatin and with the combined treatment."( Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet.
Bräsen, JH; Harsch, M; Niendorf, A, 1998
)
0.51
"02 for the dose-response relationship; P< or =0."( Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Bourassa, MG; Glass, M; Grégoire, J; Guertin, MC; L'Allier, PL; Lambert, J; Laramée, L; Lespérance, J; Reeves, F; Schwartz, L; Tardif, JC; Title, L, 2003
)
0.63
" In rats, probucol orally given 6 h after, but not simultaneous with CsA did not decrease peak CsA concentration or area under the blood CsA concentration-time curve following a single oral dosing of CsA after the pretreatment with probucol for 7 days."( Effect of probucol on the oral bioavailability of cyclosporine A.
Fujimura, A; Maezono, S; Sudoh, T; Sugimoto, K; Tsuruoka, S; Watanabe, Y; Yamamoto, Y, 2004
)
1.13
" Research and development programs are underway for a new modified release dosage form of tacrolimus (MR-4), a new analog of leflunomide (FK 778), and several novel compounds (PG 490-88, AGI 1096) in collaboration with other companies."( New drugs to improve transplant outcomes.
First, MR; Fitzsimmons, WE, 2004
)
0.32
" Dose-response curves of the probucol groups showed an improvement in endothelium-dependent relaxations, associated with increased nitric oxide bioavailability and decreased angiotensin II and hydroperoxide levels."( Role of probucol on endothelial dysfunction of epicardial coronary arteries associated with left ventricular hypertrophy.
Aubin, MC; Carrier, M; Perrault, LP; Shi, YF; Tardif, JC, 2006
)
1.06
" These data need to be confirmed in subjects receiving orally dosed AGI-1067 to be clinically relevant."( The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease.
Malinin, A; Scott, R; Serebruany, V, 2006
)
0.33
" Furthermore, chlorogenic acid significantly reduced the adhesion of human monocyte cells (U937) to IL-1beta-treated HUVECs in a dose-response manner."( Chlorogenic acid attenuates adhesion molecules upregulation in IL-1beta-treated endothelial cells.
Chang, T; Chang, WC; Chen, CH; Lee, MF; Yu, YM, 2010
)
0.36
"The purpose of this study was to develop a high-drug-loading nanoemulsion by self-assembly to improve the oral absorption of high dosing poorly water-soluble drugs."( A high-drug-loading self-assembled nanoemulsion enhances the oral absorption of probucol in rats.
Gu, W; Huang, J; Jiang, S; Li, Y; Liu, Z; Yu, H; Zhang, Z, 2013
)
0.62
"Lipid-based self-emulsifying drug delivery systems (SEDDS) are usually liquids, and they can be converted into solid dosage forms by adsorbing onto silicates."( Development of solid SEDDS, VII: Effect of pore size of silica on drug release from adsorbed self-emulsifying lipid-based formulations.
Gumaste, SG; Serajuddin, ATM, 2017
)
0.46
"Sprague Dawley rats were orally administrated with probucol at different dosage or vehicle for 5 days and subjected to a CA model by electrical stimulation, followed by cardiopulmonary resuscitation (CPR)."( Probucol Protects Rats from Cardiac Dysfunction Induced by Oxidative Stress following Cardiopulmonary Resuscitation.
Che, B; Ho, D; Hou, H; Lin, V; Lu, Z; May, A; Shaw, PX; Tran, K; Xiao, X; Zhang, J, 2017
)
2.15
"The nanoencapsulation increased the plasma and brain concentration of probucol significantly compared with the mice that was given the same dosage of probucol without capsulation, and significantly suppressed the neuroinflammation and neurodegeneration."( Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration.
Al-Salami, H; Brook, E; D'Alonzo, Z; Fimognari, N; Graneri, L; Lam, V; Mamo, JC; Mooranian, A; Nesbit, M; Stephenson, A; Takechi, R, 2018
)
0.96
" This may be related to factors such as the population and the dosage and time of taking natural products involved in different studies."( Natural products: The role and mechanism in low-density lipoprotein oxidation and atherosclerosis.
Chen, W; Feng, X; Li, L; Xu, S; Zhang, L; Zhang, S, 2021
)
0.62
"Drug solubility in intestinal fluid is a key parameter controlling absorption after the administration of a solid oral dosage form."( Structured solubility behaviour in bioequivalent fasted simulated intestinal fluids.
Abuhassan, Q; Augustijns, P; Brouwers, J; Halbert, GW; Khadra, I; Pyper, K, 2022
)
0.72
"Combined therapy including destruction and complex use of different dosage forms of the drug Panavir showed higher clinical efficacy and allowed to achieve a reduction in the rate of condyloma relapses."( [HPV-associated pathology of the oral mucosa and anogenital area. (Rationale for combined therapy)].
Kabirova, AS; Kapralova, NG; Ruvinskaya, GR; Silantieva, EN; Yunusova, EI, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
anticholesteremic drugA substance used to lower plasma cholesterol levels.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
anti-inflammatory drugA substance that reduces or suppresses inflammation.
cardiovascular drugA drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dithioketalA dithioacetal of formula R2C(SR')2, R =/= H, R' =/= H.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency2.51190.044717.8581100.0000AID485341
USP1 protein, partialHomo sapiens (human)Potency25.11890.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency6.51310.000811.382244.6684AID686978
Microtubule-associated protein tauHomo sapiens (human)Potency8.53980.180013.557439.8107AID1468
AR proteinHomo sapiens (human)Potency33.49150.000221.22318,912.5098AID1259243
EWS/FLI fusion proteinHomo sapiens (human)Potency11.07900.001310.157742.8575AID1259252; AID1259253; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency4.06450.000214.376460.0339AID720692
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency6.007019.739145.978464.9432AID1159509
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency7.07950.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)IC50 (µMol)14.00000.04002.099810.0000AID281902
Vascular cell adhesion protein 1Homo sapiens (human)IC50 (µMol)50.00006.00006.50007.0000AID216494
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
NAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)IC50 (µMol)1.60000.10003.38006.6000AID1742983
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (98)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
ossificationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
negative regulation of adaptive immune responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylethanolamine biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of cell-substrate adhesionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
bone mineralizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of actin filament polymerizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
response to endoplasmic reticulum stressPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to interleukin-13Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
wound healingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
apoptotic cell clearancePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to calcium ionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of engulfment of apoptotic cellPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
response to hypoxiaVascular cell adhesion protein 1Homo sapiens (human)
chronic inflammatory responseVascular cell adhesion protein 1Homo sapiens (human)
inflammatory responseVascular cell adhesion protein 1Homo sapiens (human)
cell adhesionVascular cell adhesion protein 1Homo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesVascular cell adhesion protein 1Homo sapiens (human)
leukocyte cell-cell adhesionVascular cell adhesion protein 1Homo sapiens (human)
cell-matrix adhesionVascular cell adhesion protein 1Homo sapiens (human)
response to nutrientVascular cell adhesion protein 1Homo sapiens (human)
amine metabolic processVascular cell adhesion protein 1Homo sapiens (human)
response to zinc ionVascular cell adhesion protein 1Homo sapiens (human)
response to ionizing radiationVascular cell adhesion protein 1Homo sapiens (human)
membrane to membrane dockingVascular cell adhesion protein 1Homo sapiens (human)
B cell differentiationVascular cell adhesion protein 1Homo sapiens (human)
response to lipopolysaccharideVascular cell adhesion protein 1Homo sapiens (human)
cell-cell adhesion mediated by integrinVascular cell adhesion protein 1Homo sapiens (human)
heterotypic cell-cell adhesionVascular cell adhesion protein 1Homo sapiens (human)
response to nicotineVascular cell adhesion protein 1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular cell adhesion protein 1Homo sapiens (human)
positive regulation of T cell proliferationVascular cell adhesion protein 1Homo sapiens (human)
response to ethanolVascular cell adhesion protein 1Homo sapiens (human)
leukocyte tethering or rollingVascular cell adhesion protein 1Homo sapiens (human)
cell chemotaxisVascular cell adhesion protein 1Homo sapiens (human)
innervationVascular cell adhesion protein 1Homo sapiens (human)
cardiac neuron differentiationVascular cell adhesion protein 1Homo sapiens (human)
cellular response to tumor necrosis factorVascular cell adhesion protein 1Homo sapiens (human)
cellular response to amyloid-betaVascular cell adhesion protein 1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrion organizationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
regulation of ketone biosynthetic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
response to nutrient levelsNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deglutarylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (42)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
integrin bindingVascular cell adhesion protein 1Homo sapiens (human)
primary amine oxidase activityVascular cell adhesion protein 1Homo sapiens (human)
cell adhesion molecule bindingVascular cell adhesion protein 1Homo sapiens (human)
cell adhesion mediator activityVascular cell adhesion protein 1Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
zinc ion bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-malonyllysine demalonylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-succinyllysine desuccinylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-glutaryllysine deglutarylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+ bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
lipid dropletPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmic side of plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membraneVascular cell adhesion protein 1Homo sapiens (human)
podosomeVascular cell adhesion protein 1Homo sapiens (human)
extracellular spaceVascular cell adhesion protein 1Homo sapiens (human)
early endosomeVascular cell adhesion protein 1Homo sapiens (human)
endoplasmic reticulumVascular cell adhesion protein 1Homo sapiens (human)
Golgi apparatusVascular cell adhesion protein 1Homo sapiens (human)
plasma membraneVascular cell adhesion protein 1Homo sapiens (human)
microvillusVascular cell adhesion protein 1Homo sapiens (human)
external side of plasma membraneVascular cell adhesion protein 1Homo sapiens (human)
cell surfaceVascular cell adhesion protein 1Homo sapiens (human)
filopodiumVascular cell adhesion protein 1Homo sapiens (human)
sarcolemmaVascular cell adhesion protein 1Homo sapiens (human)
apical part of cellVascular cell adhesion protein 1Homo sapiens (human)
extracellular exosomeVascular cell adhesion protein 1Homo sapiens (human)
alpha9-beta1 integrin-vascular cell adhesion molecule-1 complexVascular cell adhesion protein 1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
nucleusNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
cytosolNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (347)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID397350Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1325493Drug level in plasma (unknown origin)2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID397169Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1325480Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of AAPH-derived peroxyl radicals-induced lipid hydroperoxide formation by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID397353Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID397547Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397577Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID248249Concentration required for inhibition of Cu+2-induced peroxidation in low-density lipoprotein of human2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Antioxidant activities of a new lignan and a neolignan from Saururus chinensis.
AID397384Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 30 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID276033Antioxidant activity against human plasma LDL oxidation by TBARS assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata.
AID111635In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 200 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1325486Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of NpEP-derived singlet oxygen-induced lipid oxidation by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID256805Ability to inhibit HMEC1-mediated LDL oxidation at 10 uM evaluated by TBARS formation in the presence of copper2005Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26
Design, synthesis, and evaluation of pharmacological properties of cinnamic derivatives as antiatherogenic agents.
AID102499In vitro ability to protect human LDL against Cu2+-induced peroxidation. (concentration inhibiting 50% of the Cu2+ induced lipid peroxidation)2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Novel 3,5-diaryl pyrazolines and pyrazole as low-density lipoprotein (LDL) oxidation inhibitor.
AID397153Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL preincubated for 1 hr before Cu2+ challenge2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397573Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397572Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1325479Antioxidant activity assessed as inhibition of AAPH-derived peroxyl radicals-induced PGR consumption2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID281906Inhibition of LPS-induced IL6 secretion in human PBMN cells by ELISA2004Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
AID111636In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID397339Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 45 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1134503Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum cholesterol level at 0.25 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID397364Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 360 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID397337Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 15 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1128737In vivo antidyslipidemic activity against Triton WR 1339-induced hyperlipidemic Wistar rat model assessed as decrease in total cholesterol level in plasma at 56 umol/kg, ip administered as single dose 1 hr after Triton WR 1339 challenge measured after 24 2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID408062Protection against oxidized LDL-induced cytotoxicity in HMEC1 cells assessed as residual cell viability after 24 hrs by MTT assay relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Development of novel antiatherogenic biaryls: design, synthesis, and reactivity.
AID397373Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 15 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397549Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID403308Antioxidant activity assessed as DPPH radical scavenging activity by HPLC2004Journal of natural products, Jul, Volume: 67, Issue:7
New lamellarin alkaloids from the Indian ascidian Didemnum obscurum and their antioxidant properties.
AID1134505Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum triglyceride level at 0.25 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID527613Antidyslipidemic activity against triton WR-1339-induced hyperlipidemia in rat assessed as reduction in plasma LDL-cholesterol level at 56 umol/kg, ip after 24 hrs relative to control2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Design of more potent squalene synthase inhibitors with multiple activities.
AID397166Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397161Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397376Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID397555Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 360 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID29847Distribution of compound into HDL lipoprotein fraction of WHHL Rabbit's plasma after oral administration2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID397369Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397346Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID102500Tested for inhibition of copper induced lipid peroxidation in human low density lipoproteins (LDL)1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Novel indole-2-carboxamide and cycloalkeno[1,2-b]indole derivatives. Structure-activity relationships for high inhibition of human LDL peroxidation.
AID397371Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID381193Antioxidant activity against copper-induced lipid peroxidation in human LDL after 1 hr relative to probucol1999Journal of natural products, Sep, Volume: 62, Issue:9
Antioxidant principles from Ephemerantha lonchophylla.
AID172200Compound was tested for effect on liver weight after oral administration of 30 mg/kg in male rats.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID111644In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID397570Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397379Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID223094Percent decrease in Total Low density lipoproteins was determined after intraperitoneal administration of a dose of 56 uM/kg2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity.
AID377004Antioxidant activity assessed as inhibition of LDL oxidation2006Journal of natural products, May, Volume: 69, Issue:5
Phenolic compounds from the roots of Lindera fruticosa.
AID397567Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID334586Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins by spectrophotometry2002Journal of natural products, May, Volume: 65, Issue:5
2,3,4-Trimethyl-5,7-dihydroxy-2,3-dihydrobenzofuran, a novel antioxidant, from Penicillium citrinum F5.
AID397162Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397338Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 30 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID166670Compound concentration in low-density lipoprotein (LDL).1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
AID397566Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 45 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID102495Antioxidant effect on the Cu2+-mediated oxidation and apoB-100 fragmentation in LDL after incubation with 5 uM of compound2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Novel 3,5-diaryl pyrazolines and pyrazole as low-density lipoprotein (LDL) oxidation inhibitor.
AID173368Hypolipidemic activity as percentage decrease in plasma levels of the triglyceride at 56 uM/kg administered intraperitoneally in rats2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents.
AID397343Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID527612Antidyslipidemic activity against triton WR-1339-induced hyperlipidemia in rat assessed as reduction in plasma total cholesterol level at 56 umol/kg, ip after 24 hrs relative to control2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Design of more potent squalene synthase inhibitors with multiple activities.
AID628337Antioxidant activity against CuSO4-induced LDL oxidation assessed as increase in lag time at 5 uM2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID397576Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 45 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397545Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID184106Liver weight in Wistar-Imamichi rats at 200 mg/Kg dose in 12 rats1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1405920Antioxidant activity in human THP1 cells assessed as inhibition of macrophage-mediated LDL oxidation after 24 hrs in presence of CuSO4 by TBARS assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Current progress on antioxidants incorporating the pyrazole core.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID230859Molar content of compound in low-density lipoprotein (LDL) was obtained from the ratio of molecules to that of LDL particles.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
AID111641In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1325481Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of SIN-1-derived peroxynitrite-induced lipid oxidation by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID334589Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL preincubated for 1 hr before Cu2+ challenge2002Journal of natural products, May, Volume: 65, Issue:5
Anti-lipid-peroxidative principles from Tournefortia sarmentosa.
AID1742983Inhibition of SIRT5 (unknown origin)2020European journal of medicinal chemistry, Nov-15, Volume: 206Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1128732Inhibition of bovine COX-1 assessed as PGF2-alpha formation using arachidonic acid as substrate at 20 uM by enzyme immunoassay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID397351Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397383Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 15 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397382Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID736220Antioxidant activity against CuSO4-induced human LDL oxidation assessed as increase in lag time at 5 uM incubated for 5 mins prior to CuSO4 addition measured every 10 mins for 5 hrs by spectrophotometric analysis relative to control2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID100078Inhibition of LDL oxidation induced by cupric ions (CuSO4) at 1 uM expressed as % control.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID397367Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397358Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397354Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397333Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID172204Compound was tested for effect on serum LDL after oral administration of 30 mg/kg in male rats1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID216494Inhibition of TNF-alpha inducible Vascular cell adhesion molecule-1 expression.2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID358925Antioxidant activity assessed as inhibition of LDL oxidation in human plasma2001Journal of natural products, Dec, Volume: 64, Issue:12
Low-density lipoprotein-antioxidant constituents of Saururus chinensis.
AID397562Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397558Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID281903Inhibition of LPS-induced TNFalpha secretion in human PBMN cells by ELISA2004Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
AID397171Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397380Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID184561Inhibition of [Fe(2+)]/ascorbate-induced lipid peroxidation at 10e-5 M in rat brain homogenate1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID28408Distribution of compound into WHHL Rabbit's plasma after oral administration2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID397165Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1325477Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of AAPH-derived peroxyl radicals-induced pyranine consumption at 50 uM2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID397386Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397362Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID250490Effect of compound (1 uM) on macrophage-mediated oxidation of LDL was measured by MDA levels in the presence of Cu2+2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Antioxidant activities of a new lignan and a neolignan from Saururus chinensis.
AID397585Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation preincubated for 1 hr before Cu2+ challenge2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID226841Inhibition of MCLA chemiluminescence generated by autoxidation of linoleic acid2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID397342Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1515596Inhibition of SQS in rat liver microsomes assessed as reduction in [3H]FPP conversion to squalene preincubated for 10 mins followed by [3H]FPP addition and measured after 10 mins by scintillation counting method2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Optimizing the Pharmacological Profile of New Bifunctional Antihyperlipidemic/Antioxidant Morpholine Derivatives.
AID397378Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397578Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397335Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397365Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID281902Inhibition of 15-lipoxygenase by LMB assay2004Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID75288In vitro glutathione peroxidase activity at 2*10e-7M using tert-butyl hydroperoxide, activity given in percentage of ebselen''s activity1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID397387Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID341882Inhibition of LDL oxidation in genetically hypercholesterolemic KHC rabbit plasma assessed as malonaldehyde level after 1 hr2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid.
AID736211Antidyslipidemic activity against triton WR1339-induced hyperlipidemia in rat assessed as reduction in plasma triglyceride level at 56 umol/kg, ip after 24 hrs (Rvb = 580%)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
AID628457Antidyslipidemic activity in rat hyperlipidemic model assessed as decrease is plasma triglyceride level at 56 umol/kg, ip after 24 hrs relative to control2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents.
AID1128733Inhibition of human recombinant COX-2 assessed as PGF2-alpha formation using arachidonic acid as substrate at 20 uM by enzyme immunoassay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID397355Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID102493Antioxidant effect on the Cu2+-mediated oxidation and apoB-100 fragmentation in LDL after incubation with 10 uM of compound2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Novel 3,5-diaryl pyrazolines and pyrazole as low-density lipoprotein (LDL) oxidation inhibitor.
AID397349Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 45 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID397553Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID21879Calculated partition coefficient (clogP)2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity.
AID167029Compound concentration in serum.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
AID27547Distribution of compound into LDL lipoprotein fraction of WHHL Rabbit's plasma after oral administration2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID736212Antidyslipidemic activity against triton WR1339-induced hyperlipidemia in rat assessed as reduction in plasma total cholesterol level at 56 umol/kg, ip after 24 hrs (Rvb = 260%)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
AID397546Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1325485Inhibition of 15-LOX-mediated lipid oxidation in 10% C57BL/6J mouse plasma at 30 uM2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID397370Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID628336Antioxidant activity in rat hepatic microsomes assessed as inhibition of lipid peroxidation by spectrophotometric analysis2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents.
AID397374Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 30 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397579Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID300693Effect on HMEC1 cells-mediated LDL oxidation at 10 uM after 6 hrs by TBARS assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Synthesis of ferulic ester dimers, functionalisation and biological evaluation as potential antiatherogenic and antiplasmodial agents.
AID111630In vivo activity against hypocholesterol (CHOL) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 200 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID360575Antioxidant activity assessed as inhibition of endothelial cell-induced human LDL oxidation1995Journal of natural products, Dec, Volume: 58, Issue:12
Synthesis and evaluation of 3',5'-di-tert-butyl-4'-hydroxyflavones as potential inhibitors of low density lipoprotein (LDL) oxidation.
AID397551Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID89972Inhibition of proliferation of human aortic smooth muscle cells at a concentration of 5 uM; NE is no Effect2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
AID111643In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 200 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID120249Effect against totla cholesterol in high cholesterol fed mice when treated with 0.1% wt/wt diet of compound for 10 days; On day 0 =92.8 mg/dL2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Human ACAT-1 and -2 inhibitory activities of saucerneol B, manassantin A and B isolated from Saururus chinensis.
AID281900Inhibition of TNF-alpha-stimulated VCAM1 expression in endothelial cells at 100 uM2004Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
AID29926Distribution of compound into VLDL lipoprotein fraction of WHHL Rabbit's plasma after oral administration2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID100080Inhibition of LDL oxidation induced by soybean lipoxygenase (SLO) at 0.5 uM expressed as % control.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID397340Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397170Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1325476Antioxidant activity assessed as inhibition of Meo-AMVN-derived peroxyl radicals-induced fucoxanthin consumption at 50 uM2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID300695Cytoprotective effect on HMEC1 cells assessed as cell viability by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Synthesis of ferulic ester dimers, functionalisation and biological evaluation as potential antiatherogenic and antiplasmodial agents.
AID397366Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID300696Cytoprotective effect on HMEC1 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Synthesis of ferulic ester dimers, functionalisation and biological evaluation as potential antiatherogenic and antiplasmodial agents.
AID235285Free radical scavenging assessed as DPPH color reduction2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Novel 3-O-acyl mesquitol analogues as free-radical scavengers and enzyme inhibitors: synthesis, biological evaluation and structure-activity relationship.
AID250668Antioxidant activity on copper-induced peroxidation in low-density lipoprotein at 10 uM; expressed as area of absorbance/mm2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Antioxidant activities of a new lignan and a neolignan from Saururus chinensis.
AID628456Antidyslipidemic activity in rat hyperlipidemic model assessed as decrease is plasma LDL level at 56 umol/kg, ip after 24 hrs relative to control2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents.
AID13254871-octanol-water partition coefficient, log P of the compound2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID172202Compound was tested for effect on serum HDL after oral administration of 30 mg/kg in male rats1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID397332Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397377Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397368Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397168Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 360 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID111631In vivo activity against hypocholesterol (CHOL) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID172206Compound was tested for effect on serum VLDL after oral administration of 30 mg/kg in male rats1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID166672Prevention of Cu2+-induced lipid peroxidation of LDL.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID397356Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID173364Hypolipidemic activity as percentage decrease in plasma levels of the LDL-cholesterol at 56 uM/kg administered intraperitoneally in rats2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents.
AID397556Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397574Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 15 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID172198Compound was tested for effect on body weight after oral administration of 30 mg/kg in male rats.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID397550Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397559Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1499670Antioxidant activity assessed as DPPH radical scavenging activity measured at 30 to 60 mins by UV-Visible spectrophotometric method2017European journal of medicinal chemistry, Sep-29, Volume: 138Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID397360Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397552Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID527614Antidyslipidemic activity against triton WR-1339-induced hyperlipidemia in rat assessed as reduction in plasma triglyceride level at 56 umol/kg, ip after 24 hrs relative to control2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Design of more potent squalene synthase inhibitors with multiple activities.
AID250669Antioxidant activity on copper-induced peroxidation in low-density lipoprotein at 20 uM; expressed as area of absorbance/mm2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Antioxidant activities of a new lignan and a neolignan from Saururus chinensis.
AID281904Inhibition of LPS-induced IL1-beta secretion in human PBMN cells by ELISA2004Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID403309DPPH radical scavenging activity assessed as ratio of IC50 for trolox to IC50 for test compound2004Journal of natural products, Jul, Volume: 67, Issue:7
New lamellarin alkaloids from the Indian ascidian Didemnum obscurum and their antioxidant properties.
AID397560Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID179764In vitro inhibitory activity against rat microsomal lipid peroxidation (m-LPO)1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID173366Hypolipidemic activity as percentage decrease in plasma levels of the cholesterol at 56 uM/kg administered intraperitoneally in rats2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents.
AID26958cLogP was determined2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1325482Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of NaOCl-induced lipid oxidation by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID100079Inhibition of LDL oxidation induced by cupric ions (CuSO4) at 10 uM expressed as % control.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID166963Percent atherosclerotic lesions in WHHL rabbits.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
AID250223Antioxidant activity was determined by measuring the produced thiobarbituric acid reactive substance2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Synthesis of cinnamic acid derivatives and their inhibitory effects on LDL-oxidation, acyl-CoA:cholesterol acyltransferase-1 and -2 activity, and decrease of HDL-particle size.
AID111628In vivo activity against hypocholesterol (CHOL) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID397361Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397372Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 360 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID256806Cytotoxic effect of LDL oxidized by HMEC1 cells at 10 uM by MTT assay expressed as percentage of viability in unstimulated control2005Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26
Design, synthesis, and evaluation of pharmacological properties of cinnamic derivatives as antiatherogenic agents.
AID397554Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397344Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID243549Percent inhibition of Acyl-CoA:cholesterol acyltransferase-1 expressed in Hi-5 cells2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Synthesis of cinnamic acid derivatives and their inhibitory effects on LDL-oxidation, acyl-CoA:cholesterol acyltransferase-1 and -2 activity, and decrease of HDL-particle size.
AID397389Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID166663Compound was evaluated for the ability to lower total serum cholesterol levels in 4 Watanabe heritable hyperlipidemic (WHHL) rabbits on day 28.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
AID397352Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID109969Effect against body weight of mice when treated with 0.1% wt/wt diet of compound for 10 days; On day 0 =21.8 g2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Human ACAT-1 and -2 inhibitory activities of saucerneol B, manassantin A and B isolated from Saururus chinensis.
AID223099Percent decrease in Total Triglycerides was determined after intraperitoneal administration of a dose of 56 uM/kg2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity.
AID397334Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397381Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID736224Antioxidant activity in rat hepatic microsomes assessed as inhibition of lipid peroxidation after 45 mins by spectrophotometric analysis2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
AID159564Compound was tested for inhibition of Cu2+ catalyzed LDL oxidation and the potency relative to terbufucine was determined1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID407779Antioxidant activity in HMEC1 cells assessed as inhibition of LDL oxidation at 10 uM after 6 hrs by TBARS assay relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Development of novel antiatherogenic biaryls: design, synthesis, and reactivity.
AID397568Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID397341Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397357Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID159534In vitro inhibition of Cu2+ catalyzed LDL oxidation1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID628455Antidyslipidemic activity in rat hyperlipidemic model assessed as decrease is plasma total cholesterol level at 56 umol/kg, ip after 24 hrs relative to control2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents.
AID1499669Antioxidant activity in heat-inactivated Fischer-344 rat hepatic microsomes assessed as protection against against Fe2+/ascorbate-induced lipid peroxidation after 45 mins by TBAR-based spectrophotometry2017European journal of medicinal chemistry, Sep-29, Volume: 138Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID397557Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 90 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397163Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID397548Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 60 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID166662Compound was evaluated for the ability to lower total serum cholesterol levels in 4 Watanabe heritable hyperlipidemic (WHHL) rabbits on day 0.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
AID27917Calculated partition coefficient (clogP)2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID184572Inhibition of spontaneous lipid peroxidation at 10e-5 M in rat brain homogenate1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID397347Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 15 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397571Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397388Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID100081Inhibition of LDL oxidation induced by soybean lipoxygenase (SLO) at 5 uM expressed as % control.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID397561Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397575Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 30 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397563Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 360 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397359Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397580Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1128712Antioxidant activity in rat liver microsome membrane assessed as inhibition of lipid peroxidation after 45 mins by TBARS-based spectrophotometric assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID1128731Inhibition of squalene synthase in rat liver microsomes assessed as decrease in conversion of [3H]FPP to squalene2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID111633In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID397581Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 180 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397584Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation preincubated for 1 hr before Cu2+ challenge2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1499671Inhibition of SQS in rat microsomes using [3H]-FPP as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by scintillation counting2017European journal of medicinal chemistry, Sep-29, Volume: 138Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity.
AID313419Antioxidant activity assessed as inhibition of LDL-oxidation at 20 uM by TBARS assay2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Low-density lipoprotein (LDL)-antioxidant lignans from Myristica fragrans seeds.
AID1128714Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID397375Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 45 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID313422Antioxidant activity against LDL-oxidation assessed as conjugated diene formation lag time at 3.0 uM2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Low-density lipoprotein (LDL)-antioxidant lignans from Myristica fragrans seeds.
AID397582Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397336Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as lysophosphatidylcholine formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 360 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397167Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID223102Percent decrease in Total cholesterol was determined after intraperitoneal administration of a dose of 56 uM/kg2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity.
AID397363Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397564Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 15 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID102494Antioxidant effect on the Cu2+-mediated oxidation and apoB-100 fragmentation in LDL after incubation with 20 uM of compound2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Novel 3,5-diaryl pyrazolines and pyrazole as low-density lipoprotein (LDL) oxidation inhibitor.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID397565Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 30 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397385Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 10 umol/L preincubated for 1 hr before Cu2+ challenge measured after 45 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID313420Antioxidant activity against LDL-oxidation by TBARS assay2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Low-density lipoprotein (LDL)-antioxidant lignans from Myristica fragrans seeds.
AID1128738In vivo antidyslipidemic activity against Triton WR 1339-induced hyperlipidemic Wistar rat model assessed as decrease in LDL-cholesterol level in plasma at 56 umol/kg, ip administered as single dose 1 hr after Triton WR 1339 challenge measured after 24 hr2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID397348Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 30 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID397583Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as maximal compound concentration at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 270 mins relative to compound present at 0 min2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1128739In vivo antidyslipidemic activity against Triton WR 1339-induced hyperlipidemic Wistar rat model assessed as decrease in triglyceride level in plasma at 56 umol/kg, ip administered as single dose 1 hr after Triton WR 1339 challenge measured after 24 hrs2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID1134507Toxicity in Sprague-Dawley rat assessed as increase in liver weight at 0.25 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID397569Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 20 umol/L preincubated for 1 hr before Cu2+ challenge measured after 120 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID341881Inhibition of lipid peroxidation in genetically hypercholesterolemic KHC rabbit serum assessed as malonaldehyde level after 4 hrs2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid.
AID397164Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as conjugated diene formation at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 150 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1515594Antioxidant activity in rat hepatic microsomes assessed as reduction in ferrous salt/ascorbic acid-induced lipid peroxidation of membrane lipids by measuring TBARS level after 45 mins by spectrophotometric method2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Optimizing the Pharmacological Profile of New Bifunctional Antihyperlipidemic/Antioxidant Morpholine Derivatives.
AID166665Compound was evaluated for the ability to lower total serum cholesterol levels in 4 Watanabe heritable hyperlipidemic (WHHL) rabbits on day 84.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
AID360576Antioxidant activity assessed as inhibition of copper-induced human LDL oxidation1995Journal of natural products, Dec, Volume: 58, Issue:12
Synthesis and evaluation of 3',5'-di-tert-butyl-4'-hydroxyflavones as potential inhibitors of low density lipoprotein (LDL) oxidation.
AID397345Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL assessed as vitamin E consumption at 5 umol/L preincubated for 1 hr before Cu2+ challenge measured after 210 mins2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID166664Compound was evaluated for the ability to lower total serum cholesterol levels in 4 Watanabe heritable hyperlipidemic (WHHL) rabbits on day 56.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346926Human ABCA1 (ABCA subfamily)2004The Journal of biological chemistry, Jul-16, Volume: 279, Issue:29
Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation.
AID1346926Human ABCA1 (ABCA subfamily)2004Arteriosclerosis, thrombosis, and vascular biology, Dec, Volume: 24, Issue:12
Probucol inhibits ABCA1-mediated cellular lipid efflux.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,408)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990271 (19.25)18.7374
1990's469 (33.31)18.2507
2000's326 (23.15)29.6817
2010's278 (19.74)24.3611
2020's64 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.14 (24.57)
Research Supply Index7.42 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index69.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials174 (11.69%)5.53%
Reviews154 (10.35%)6.00%
Case Studies42 (2.82%)4.05%
Observational0 (0.00%)0.25%
Other1,118 (75.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (22)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy [NCT01252056]Phase 4353 participants (Actual)Interventional2010-03-31Completed
Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety in Peripheral Artery Disease Subjects Complicated With Coronary Artery Disease. [NCT01142284]Phase 280 participants (Actual)Interventional2010-05-19Completed
Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study [NCT01291641]Phase 4342 participants (Actual)Interventional2011-03-31Completed
[NCT02098460]Phase 4250 participants (Anticipated)Interventional2013-10-31Recruiting
A Randomized, Double Blind, Placebo Control, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Imported Probucol in Hyperlipidemia Patients [NCT01349010]Phase 3264 participants (Actual)Interventional2011-04-30Completed
A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker [NCT00823849]Phase 4200 participants (Actual)Interventional2008-10-31Completed
Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol [NCT02483169]Phase 4800 participants (Anticipated)Interventional2009-06-30Active, not recruiting
[NCT02196805]120 participants (Anticipated)Interventional2009-03-31Completed
The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques: a Prospective, Random, Single-center Study Based on High Resolution Magnetic Resonance Imaging [NCT03753555]Phase 4100 participants (Anticipated)Interventional2018-12-01Recruiting
[NCT01031667]Phase 4118 participants (Actual)Interventional2009-11-30Completed
Dose-finding and Proof-of-concept Trial of Probucol to Increase Availability of CSF Apolipoprotein-E [NCT02707458]Phase 1/Phase 223 participants (Actual)Interventional2016-04-30Completed
A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and [NCT01013532]Phase 41,600 participants (Anticipated)Interventional2009-06-30Active, not recruiting
A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject [NCT00823875]Phase 4200 participants (Anticipated)Interventional2009-03-31Completed
AGI-1067 as a Novel Antidiabetic Agent Evaluation Study [NCT00525577]Phase 2/Phase 31,012 participants (Anticipated)Interventional2007-08-31Active, not recruiting
Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis [NCT00598533]Phase 43,002 participants (Actual)Interventional2008-02-29Completed
A Prospective Randomized, Controlled, Open-labeled Trial of Probucol Combined With Valsartan in Patients With Diabetes Nephropathy [NCT00655330]170 participants (Anticipated)Interventional2008-05-31Active, not recruiting
Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy [NCT00276133]Phase 424 participants (Actual)Interventional2004-01-31Completed
A Randomized, Open-label, Single-center Clinical Trial to Evaluate the Safety and Pharmacokinetics of Probucol by Multiple Administration in Healthy Male Subjects [NCT01000467]Phase 430 participants (Actual)Interventional2009-02-28Completed
The Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects [NCT01590901]Phase 112 participants (Actual)Interventional2012-02-29Completed
Phase IV, Safety and Pharmacokinetics of Probucol and Cilostazol When Coadministered in Healthy Subjects [NCT00549978]Phase 432 participants (Actual)Interventional2007-10-31Completed
A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy [NCT00426348]Phase 475 participants (Actual)Interventional2007-05-31Completed
A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes. [NCT01726816]Phase 2126 participants (Actual)Interventional2012-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]